CONFIDENTIA L
The GlaxoSmithKline group of companies 202152
1Division :World wide Development
Information Type :Reporting and Anal ysis Plan (RAP)
Title :Reporting and An alysis Plan for Study  202152: A 
multicentre, randomised, double -blind (sponsor -unblinded), 
placebo- controlled study  with open label extension to 
investigate the safet y and tolerability , pharmacokinetics, 
pharmacod ynamics, and efficacy  of GSK2982772 in subjects 
with active ulcerative colitis.
Compound Number :GSK2982772
Effective Date :18-Jul-2019
Description:
The purpose of this RAP is to describe the planned anal yses and output to be 
included in the Clinical Study  Report (CSR) for Protocol 202152.
This R AP is intended to describe the interim and final a nalyses required for the 
study .
This RAP will be provided to the study  team members to convey  the content of the 
Statistical Analy sis Complete ( SAC ) deliverable.
RAP Author(s):
Author’s Name and Functional Area: 
15-JUL-2019Principal Statistician ( IIClinical Statistics)
15-JUL-2019Statistics Manager (IIClinical Statistics)
Copy right 2020 the GlaxoSmithKline group of companies. All rights reserved.  
Unauthorised cop ying or use of this information is prohibited. 2019N425893_00
PPD
PPD
CONFIDENTIA L
The GlaxoSmithKline group of companies 202152
2RAP Team Review Confirmation :
(Email)
Reviewer Date
Principal Programmer /Analy st (Clinical 
Programming)16-JUL-2019
16-JUL-2019 Operations and Science Lead (II Global Clinical 
& Data Operations)
16-JUL-2019 Clinical I nvestigational Lead, Discovery  
Medicine
 16-JUL-2019Director, CPMS
Project Phy sician Lead, iiTA16-JUL-2019
Senior Medical Director, GCSP SERM16-JUL-2019
15-JUL-2019 Data Qualit y Lead (II Global Clinical & Data 
Operations)
Clinical Statistics and Clin ical Programming Line Approvals:
(PharmaTMF signoff)
Approver Date
18-JUL-2019Snr Statistical Director (II Clinical Statistics)
18-JUL-2019Programming Manager (II Clinical Programming) 2019N425893_00
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
CONFIDENTIA L
202152
3TABLE OF CONTENTS
PAGE
1.INTRODUCTION ...................................................................................................... 6
2.SUMMARY OF KEY PROTO COL INFORMATION .................................................. 6
2.1. Changes to the Protocol Defined Statistical Analysis Plan ............................ 6
2.2. Study Objective(s) and Endpoint(s) ............................................................... 7
2.3. Study Design .............................................................................................. 10
2.4. Statistical Analyses ..................................................................................... 11
3.PLANNED ANALYSES .......................................................................................... 12
3.1. Interim Analyses ......................................................................................... 12
3.2. Final Analyses ............................................................................................ 13
4.ANALYSIS POPULATIONS ................................................................................... 13
4.1. Protocol Deviations ..................................................................................... 13
5.CONSIDERATIONS FOR D ATA ANALYSES AND DATA HANDLING 
CONVENTIONS ..................................................................................................... 14
5.1. Study Treatment & Sub -group Display Descriptors ..................................... 14
5.2. Baseline Definitions .................................................................................... 15
5.2.1. Derivations and Handling of Missing Baseline Data ..................... 17
5.3. Multicentre Studies ..................................................................................... 17
5.4. Examination of Covariates, Other Strata and Subgroups ............................ 17
5.5. Multiple Comparisons and Multiplicity ......................................................... 17
5.6. Other Considerations for Data Analyses and Data Handling 
Conventions ................................................................................................ 17
6.STUDY POPULATION ANA LYSES ....................................................................... 18
6.1. Overview of Planned Study Population Analyses ........................................ 18
6.1.1. Study Population Summary Measure ........................................... 18
7.SAFETY ANALYSES ............................................................................................. 20
7.1. Adverse Events Analyses ........................................................................... 20
7.1.1. Adverse Event Summary Measures ............................................. 20
7.2.Clinical Laboratory Analyses ....................................................................... 21
7.2.1. Clinical Laboratory Summary Measures ...................................... 21
7.3. Other Safety Analyses ................................................................................ 22
7.3.1. Summary Measures ..................................................................... 22
7.4. Other Safety Analyses ................................................................................ 23
8.EFFICACY ............................................................................................................. 24
8.1. Efficacy Endpoints ...................................................................................... 24
8.1.1. Population of Interest ................................................................... 25
8.1.2. Statistical Analyses / Methods ..................................................... 25
8.1.2.1. Statistical Methodology Specification .......................... 25
8.1.2.1.1 Continuous Endpoints ................................................ 25
8.1.2.1.2 Binary Endpoints ........................................................ 26
8.2. Exploratory Effic acy Analyses ..................................................................... 27
8.2.1. Responder Across Endpoints ....................................................... 27 2019N425893_00
CONFIDENTIA L
202152
48.2.2. Probabilities of Success ............................................................... 27
8.3. Exploratory Pharmacodynamic / Efficacy Analyses ..................................... 28
9.PHARMACOKINETIC ANAL YSES ......................................................................... 28
9.1. Pharmacokinetic Analyses .......................................................................... 28
9.1.1. Endpoint / Variables ..................................................................... 28
9.1.1.1. Drug Concentration Measures .................................... 28
9.1.2. Population of Interest ................................................................... 29
9.2. Population PK Analyses .............................................................................. 29
9.3. Pharmacokinetic/Pharmacodynamic Analyses ............................................ 29
10.BIOMARKER ANALYSES ...................................................................................... 30
10.1. Biomarker/Target Engagement/Pathway Engagement/ 
Transcriptomics Analyses ........................................................................... 30
10.1.1. Endpoint / Variables ..................................................................... 30
10.1.2. Population of Interest ................................................................... 31
10.1.3. Statistical Ana lyses / Methods ..................................................... 31
10.1.3.1. Statistical Methodology Specification .......................... 31
11.REFERENCES ....................................................................................................... 36
12.APPENDICES ........................................................................................................ 37
12.1. Appendix 1: Protocol Deviati on M anagement and Definitions for Per 
Protocol Population ..................................................................................... 37
12.1.1. Exclusions from Per Protocol Population ..................................... 37
12.2. Appendix 2: Schedule of Activities .............................................................. 38
12.2.1. Proto col Defined Schedule of Events ........................................... 38
12.3. Appendix 3: Assessment W indows ............................................................. 42
12.3.1. Definitions of Assessment Windows for Analyses ........................ 42
12.4. Appendix 4: Study Phases and Tr eatment Emergent Adverse 
Events ........................................................................................................ 43
12.4.1. Study Phases .............................................................................. 43
12.4.1.1. Study Phases for Concomitant Medication ................. 43
12.4.2. Treatment Emergent Flag for Adverse Events ............................. 43
12.5. Appendix 5: Data Display Standards & Handling Conventions .................... 44
12.5.1. Reporting Process ....................................................................... 44
12.5.2. Reporting Standards .................................................................... 44
12.5.3. Reportin g Standards for Pharmacokinetic .................................... 45
12.6. Appendix 6: Derived and Transformed Data ............................................... 46
12.6.1. General ........................................................................................ 46
12.6.2. Study Population .......................................................................... 46
12.6.3. Safety .......................................................................................... 47
12.6.4. Efficacy ........................................................................................ 48
12.6.5. Biomarker .................................................................................... 53
12.7. Appendix 7: Reporting Standards for Missing Data ..................................... 54
12.7.1. Premature W ithdrawals ................................................................ 54
12.7.2. Handling of Missing Data ............................................................. 54
12.7.2.1. Handling of Missing and Partial Dates ........................ 54
12.8. Appendix 8: Values of Potential Clinical Importance ................................... 55
12.8.1. Laboratory Values ........................................................................ 55
12.8.2. ECG ............................................................................................. 56
12.8.3. Vital Signs .................................................................................... 56 2019N425893_00
CONFIDENTIA L
202152
512.9. Appendix 9: Abbreviations & Trade Marks .................................................. 57
12.9.1. Abbrev iations ............................................................................... 57
12.9.2. Trademarks ................................................................................. 58
12.10. Appendix 10: List of Data Displays .............................................................. 59
12.10.1. Data Display Numbering .............................................................. 59
12.10.2. Mock Example Shell Referencing ................................................ 59
12.10.3. Deliverables ................................................................................. 59
12.10.4. Study Population Tables .............................................................. 60
12.10.5. Safety Tables ............................................................................... 63
12.10.6. Safety Figures ............................................................................. 71
12.10.7. Efficacy Tables ............................................................................ 72
12.10.8. Efficacy Figures ........................................................................... 77
12.10.9. Pharmacokinetic Tables ............................................................... 83
12.10.10. Pharmacokinetic Figures ............................................................. 84
12.10.11. Pharmacodynamic and/or Biomarker Tables ............................... 87
12.10.12.Pharmacodynamic and/or Biomarker Figures .............................. 90
12.10.13. ICH Listings ................................................................................. 95
12.10.14. Non-ICH Listings ........................................................................ 103
12.11. Appendix 11: Example Mock Shells for Data Displays .............................. 109
12.12. Appendix 12: NONMEM datafile specification ........................................... 110 2019N425893_00
CONFIDENTIA L
202152
61. INTRODUCTION
The purpose of this reporting and a nalysis plan (RAP) is to describe the analy ses to be 
included in the CSR for Protocol 202152 :
Revision Chronology:
2015N251758_00 23-MAY -2016 Original
2015N251758_01 20-APR-2017 Protocol Amendment 1 -Change in dosing regimen from 60 
mg BID to 60 mg TID, updates to Inclusion criteria 3 and 6 
and Exclusion criteria 3, 9, 21 and 22, allowance for 
rescreening, and addition of suicidality stopping criteria plus 
some minor protocol clarifications and administrative changes.
2. SUMM ARY OF K EY PROTOCOL I NFORM ATION
2.1. Changes to the Protocol Defined Statistical A nalysis Plan
Changes from the originally  planned statistical analy sis specified in the protocol are 
outlined in Table 1.
Table 1 Changes to Prot ocol Defined A nalysis Plan
Protocol Reporting & Analysis Plan
Statistical Analysis Plan Statistical Analysis Plan Rationale for Changes
Two interim analyses (IA) were 
planned. The decision whether the
first IA will be conducted was to be 
based on the rec ommendation of 
the DRC review to assess futility 
based on 6 weeks of treatment, or 
when an appropriate number have 
completed 6 weeks of treatment, 
whichever is earliest. The purpose 
of the firstIAwould be to assess 
whether to stop the study for futility 
and, if appropriate, to perform a 
sample size re -estimation. The 
second IA will occur when an 
appropriate number have
completed 12 weeks of treatment. 
The purpose of the second IAwould 
be to assess whether to stop the 
study for futility.A formal IAat 6 weeks will no 
longer be conducted based 
recommendations of the DRC. The DRC data review of the 6 
week data concluded that there 
was insufficient evidence to stop 
for futility and recommended a 
single IAto be conducted when 
an appropriate number of 
subjects have completed 12 
weeks of treatment. This DRC 
data review will be considered in 
replacement of the first IA.
Endpoints for the 3-domain partial 
Mayo , 3-domain Mayo clinical 
response and 3 -domain Mayo 
clinical remission are not specified 
in the prot ocol. Relevant definitions and required 
summaries was added to the 
RAP. The landscape for UC has 
changed since the protocol was 
developed. 
The total score for the Mayo is The RAP uses the Total Mayo To match terminology used in the  2019N425893_00
CONFIDENTIA L
202152
7Protocol Reporting & Analysis Plan
Statistical Analysis Plan Statistical Analysis Plan Rationale for Changes
called the complete Mayo in the 
Protocol.Score termi nology . FDA’s Ulcerative Colitis: Clinical 
Trial Endpoints Guidance for 
Industry document.
The scoring algorithm for the 
Modified Riley Scale in Table 7 of 
the protocol has an error where 
reverse labelling was used for the 
Historical Characteristics for mild 
and moderate disease activity. The RAP details the correct MRS 
scores as provided by Robarts 
(central reader). To fix an error in the protocol.
Further details can be found in 
the Protocol Note to File #4 
dated 24 Ma y 2018. 
No endpoint and derivations for the 
Robarts Histology Index (RHI) was 
explicitly mentioned in the protocol. 
The protocol endpoints section 
states: Change from baseline on 
histologic severity including but not 
limited to MRS and Geboes. 
Robarts w ill also provide GSK with 
the RHI alongside the MRS and 
Geboes.Relevant definitions for the RHI 
and required summaries were 
added to the RAPTo enable analysis of the RHI 
data.  
GSK2982772 plasma 
concentrations will be summarised 
descriptively by day an d nominal 
sampling time (Pre-dose on Day 43
and at 1, 2, 4, and 6 hours post 
dose on Days 1 and 43 and trough 
on Day 85 or Early Withdrawal ).The predicted trough 
concentration at 7am on Day 43 
will be calculated using the 
observed pre -dose concentration 
at the time of the PK sample (see 
Section 9.1.1.1 for calculations)
The predicted Day 43 trough 
concentration will be used in 
PK/PD assessments instead of 
the observed Day 43 Pre -Dose 
concentrationSince the half -life of 
GSK2982772 is short (2 -3h), the 
duration of time between the Day 
43 clinic visit and the usual 
dosing time (assumed to be 7am 
for all subjects) may result in the 
reported “pre- dose” 
concentration being lower than 
the true “trough concentration ”
2.2. Stud y Objective(s) and Endpoint(s)
Objectives Endpoints
Primary Objectives Primary Endpoints
To investigate the safety and tolerability 
of 60 mg three times daily doses of 
GSK2982772 in subjects with moderate 
to severe ulcerative colitis.Adverse events.
Clinical laborato ry values (clinical chemistry, 
haematology and urinalysis).
Vital sign measurements (blood pressure, heart rate, 
respiratory rate, and body temperature).
12-Lead ECG monitoring.
Secondary Objectives Secondary Endpoints
To investigate the preliminary effi cacy of 
60 mg three times daily doses of 
GSK2982772 in achieving mucosal 
healing after 6 and 12 weeks of treatment 
in subjects with active ulcerative colitis. The proportion of subjects who achieve an absolute 
Mayo endoscopy subscore of 0 or 1 at Days 43 
(Week 6) and 85 (Week 12).
Change from baseline in mucosal appearance 
determined by Ulcerative Colitis Endoscopic Index of  2019N425893_00
CONFIDENTIA L
202152
8Objectives Endpoints
Severity (UCEIS).
To investigate the effect of 60 mg three 
times daily doses of GSK2982772 on 
biomarkers of disease activity in subje cts 
with active ulcerative colitis.Change from baseline in markers which may include, 
but are not limited to, mean CRP and faecal 
calprotectin (FCP).
To investigate the effect of 60 mg t hree 
times daily doses of GSK2982772 on 
histologic disease activity in subjects with 
active ulcerative colitis.Change from baseline in histologic severity, including 
but not limited to Modified Riley Score and Geboes 
Index.
To investigate the effect of 60 mg t hree 
times daily doses of GSK2982772 in 
achieving clinical res ponse and remission 
after 6 and 12 weeks of treatment in 
subjects with active ulcerative colitis. The proportion of subjects who achieve clinical 
response defined as reduction by ≥3 points or ≥30% 
improvement from baseline complete Mayo score, 
along with a decrease in the rectal bleeding score of 
≥1 point, at Days 43 (Week 6) and 85 (Week 12).
The proportion of subjects who achieve clinical 
remission defined as a complete Mayo score of 2 
points or lower, with no individual subscore exceeding 
1 point, at Day s 43 (Week 6) and 85 (Week 12).
To investigate the preliminary efficacy of 
60 mg three times daily doses of 
GSK2982772 in achieving symptomatic 
clinical remission after 6 and 12 weeks of 
treatment in subjects with active 
ulcerative colitis.Change from ba seline in partial Mayo score.
To investigate the plasma concentrations 
of GSK2982772 following 60 mg t hree 
times daily in subjects with active 
ulcerative colitis. Pre-dose plasma concentrations of GSK2982772 at 
Day 43 (Week 6). 
 Post- dose plasma concentra tions of GSK2982772 on 
Days 1 and 43 (Week 6) at 1, 2, 4 and 6 hours.
Trough concentrations on Day 85 (Week 12).
Exploratory Objectives Exploratory Endpoints
To investigate the effect of 60 mg three 
times daily doses of GSK2982772 on 
expression of inflam matory biomarkers in 
mucosal tissue biopsies in subjects with 
active ulcerative colitis.Change fr om baseline in inflammatory markers which 
may include, but are not limited to IL -1, IL-6, IL- 8, 
MMP3, TNFα, IFNγ.
To investigate pathway and target 
engagement following 60 mg t hree times
daily doses of GSK2982772 in blood and 
colon biopsy tissue. Pharmaco logy biomarker endpoints may include, but 
are not limited to the following, pre -dose at Days 1, 
43 (Week 6) and trough on Day 85 (Week 12), as 
applicable and if evaluable samples and data permit:
oTarget Engagement Assay RiP1 (TEAR1) in 
blood and colon tiss ue.
Phosphorylated or total RIP1, MLKL, RIP3, cleaved 
and total caspase 3 and 8 signatures in colon biopsy 
tissue.
To investigate the concentration of 
GSK2982772 and possible drug -related 
material, as well as specific distribution 
within tissue if feasible, in the colon tissue Pre-dose GSK2982772 and possible drug -related 
material concentrations, as well as specific distribution 
within tissue if feasible, in colon biopsies at Days 43 
(Week 6) and 85 (Week 12), as evaluable samples  2019N425893_00
CONFIDENTIA L
202152
9Objectives Endpoints
after 60 mg t hree times daily doses of 
GSK2982772.and data permit.
To investigate the effect of 60 mg t hree 
times daily doses of GSK2982772 on 
quality of life in subjects with active 
ulcerative colitis.Change from baseline in Inflammatory Bowel Disease 
Questionnaire (IBDQ).
Toinvestigate the effect of 60 mg t hree 
times daily doses of GSK2982772 on 
gene expression in the blood in subjects 
with active ulcerative colitis.Transcriptomic analysis of mRNA isolated from blood 
Days 1 and 43 (Week 6) and trough on Day 85 (Week 
12).
To investigate the effect of 60 mg t hree 
times daily doses of GSK2982772 on 
gene expression in colon tissue biopsies 
in subjects with active ulcerative colitis.Transcriptomic analysis of mRNA isolated from colon 
tissue biopsies at Screening, and Days 43 (W eek 6) 
and trough on Day 85 (Week 12). 2019N425893_00
CONFIDENTIA L
202152
102.3. Stud y Design
Overview of Study Design and Key Features
Key assessments:
Safety assessments, PK samples, Mayo score, Modified Riley Scale , 
Geboes Index, IBDQ and PD samples
Design Features This is a multicentre , randomized, double -blind (sponsor -unblinded), placebo -
controlled (Part A) study with an open label extension (Part B) . 
Investigate the safety and tolerability, PK, PD, and preliminary efficacy of 
GSK2982772 in subjects with active U C.
Study Du ration 
and DosingEach participant will participate in the study for approximately 20 weeks. This 
includes a screening period up to 30 days, an 84 -day (12 week) treatment period, 
and a 28- dayfollow -up period after the last dose.
Within 30 days of the screening visit (defined as day of consent signing), eligible 
participants enter a 2- part treatment phase as follows with study treatment starting 
on study day 1:
oPart A : Approximately 36 participants are randomly assigned to receive either 
GSK2982772 60 mg three times daily (TID) or placebo TIDfor 42 days (6 
weeks) in a 2:1 ratio .
oPart B :Allparticipants who complete Part A move on toreceive open label 
treatment of GSK2982772 60 mg TIDfor an additional 42 days (6 weeks).  
Treatment duration is a total of 84 days (12 weeks) inclusive of Parts A and B.
Participants are followed -up for 28 days (4 weeks) after the last dose in Part B. 
Prior to amendment 01 being effective in each country, participants were randomly 
assigned to receive either: 
Part A: GSK298 2772 60 mg two times daily (BID) or placebo BID for 42 days 
(6 weeks) in a 2:1 ratio. 
Part B: Open label treatment for all participant s who have completed Part A
of GSK2982772 60 mg BID for an additional 42 days (6 weeks).  
Time & Events Refer to Appendix 2 : Schedule of Activities .
During the 84 -day(12 week) treatment period, participants attend the clinical for 
visits on Day s1, 15, 29, 43, 57, 71 and 85. 
At specific visits, participants must not take treatment prior to their scheduled 
treatment. 
On Days 8, 22, 36, 50, 64 and 78 participant s were to be contacted by telephone 
and asked about their general health. 
Participants aregiven a diary card at every visit and asked to record daily study  2019N425893_00
CONFIDENTIA L
202152
11Overview of Study Design and Key Features
medication, concomitant medication and adverse events. 
Treatment 
AssignmentAt Screening a unique CRF number (Subject Number) isassigned.
Participants who meet screening eligibility c riteria and complete pre-treatment 
assessments are randomised through an Interactive Response Technology 
System (IRTS). The IRTS confirm sthe participant’s CRF number (Subject 
Number) and provide s the randomisation number.
Therandomisation number is generated by Clinical Statistics, prior to the start of 
the study, using validated internal software.  Once a ssigned, this randomisation
number must not be reassigned to any other participant in the study.
The randomisation is centrally controlled by the IRTS.
Approximately 36 participants were randomised in a 2:1 ratio to receive 
GSK2982772 60mg TID or Placebo T ID in Part A. 
Any participant that is re -screened outside of the allowed screening window at the 
approval of the GSK Medical Monitor, must be assigned a new unique Subject 
Number.
Interim Analysis An internal GSK Safety Review Team (SRT) reviews blinded safety data at 
appropriate intervals during the study and an internal GSK Data Review 
Committee (DRC) review sunblinded safety, inflammatory biomarkers, clinical and 
mechanistic data at appropriate intervals during the study in accordance with the 
DRC Charter.
Two interim analyses were planned in the protocol to facilitate decision making 
regarding the subsequent clinical development of GSK2982772 for UC.
Interim Analysis #1 : 
Was planned to occur either on the recommendation of the DRC, or when an 
appropri ate number have completed 6 weeks of tre atment, whichever is 
earliest. 
The p urpose was to assess whether to stop the study for futility and, if 
appropriate, to perfor m a sample size re -estimation. 
Interim Analysis #2 :
Was planned to occur when an approp riate number of participants have 
completed 12 weeks of treatment. 
The purpose was to assess whether to stop the study for futility.  
A formal interim analysis at 6 weeks will no longer be conducted based on review 
of recruitment information and recommen dation by the DRC. The DRC instead 
recommended a single interim analysis to be conducted when an appropriate 
number of participants have completed 12 weeks of treatment.
The DRC data review of the 6 week data concluded that there was insufficient 
evidence to stop for futility and recommended a single interim analysis to be 
conducted when an appropriate number of participants have completed 12 weeks 
of treatment. 
This DRC data review will be considered in replacement of the first interim 
analysis .
2.4. Statist ical Analyses
The primary  objective of the study  is to investigate the safet y and tolerability of 
GSK2982772 60mg tid following 12 weeks of treatment. No formal statistical hy potheses 
will be conducted to assess this objective.  2019N425893_00
CONFIDENTIA L
202152
12If appropriate, comparisons between the GSK2982772 arm and the placebo arm will be 
made to investigate the secondary  pharmacody namic, mechanistic and efficacy  
objectives. Trends over time will be investigated for both treatment arms along with 
associations between each of the parame ters. 
3. PLANNED ANAL YSES
3.1. Interim Analyses
Two interim anal yses were planned to be conducted during the study .  Additionally , two 
review teams monitor data on an ongoing basis for routine pharmacovigilance and 
decision making regarding the subsequent clinic al development of GSK2982772 for UC.
In line with routine pharmacovigilance, an internal GSK Safet y Review Team (SRT) 
which include s members of the GSK2982772 project team, reviews blinded safet y data, 
including clinical laboratory  parameters and adverse e vents, at appropriate intervals 
during the period of study  conduct.
Once an appropriate number of participants have completed Day  43 (Week 6), mucosal 
healing will be reviewed in an unblinded manner by  the DRC consisting of the GSK 
study  physician, the st udy statistician, the study  pharmacokineticist, the PRR DPU Head, 
EDL  and SRT Leader or designees on an ongoing basis.  A phy sician external to the 
GSK2982772 project team may  also be involved in the data review. Additional 
inflammatory  biomarkers, clinica l and mechanistic endpoints (e.g. target engagement) 
may be reviewed if available. No other member of the GSK core study  team will be 
unblinded to this data. The primary  purpose of these reviews isto monitor mucosal 
healing rates.  On review of mucosal he aling data, the review group may  recommend an 
interim analy sis of key  clinical and mechanistic data is first conducted prior to any  
decision to terminate the study  for futility .  A data review charter identif iesthe specific 
GSK individuals involved; outli ne in detail the activities of this review and how the 
integrit y of the stud y will be maintained.
The timing of Interim Analy sis #1 in the protocol was either on the recommendation of 
the DRC to assess futility  based on 6 weeks of treatment, or when an ap propriate number 
have completed 6 weeks of treatment, whichever is earliest.  The purpose of Interim 
Analy sis #1 would be to assess whether to stop the study  for futility  and, if appropriate, to 
perform a sample size re -estimation.  The timing of Interim A nalysis #2 was to occur 
when an appropriate number have completed 12 weeks of treatment.  The purpose of the 
Interim Anal ysis #2 was to assess whether to stop the study  for futility .  
A formal interim anal ysis at 6 weeks will no longer be conducted based on review of 
recruitment information and recommendation by  the DRC. The DRC data review of the 6 
week data concluded that there was insufficient evidence to stop for futility  and 
recommended a single interim anal ysis be conducted when an appropriate numbe r of 
participants have completed 12 weeks of treatment. This DRC data review will be 
considered in replacement of the first interim analy sis. 2019N425893_00
CONFIDENTIA L
202152
133.2. Final A nalyses
The final planned primary  analy ses will be performed after the completion of the 
following sequen tial steps:
1.All participants have completed the study  as defined in the protocol.
2.All required database cleaning activities have been completed and final database 
release and database freeze has been declared by  Data Management.
3. All criteria for unblinding the randomisation codes have been met. 
4.Randomisation codes have been distributed perRandAll NG procedures.
4. ANALYSIS P OPUL ATIONS
Population Definition / Criteria Analyses Evaluated
All Subjects Comprises of all participants who were screened for 
the study .Selected Study 
Population
Safety Comprise of all participant s who receive at least one 
dose of study treatment.Study Population
Safety
Efficacy
PD
Biomarker
Pharmacokinetic Participants in the ‘Safety’ population who received an 
active dose and fo r whom a GSK2982772 
pharmacokinetic sample was obtained and analysed.PK
Per Protocol (PP) All participants in the Safety population who comply 
with the protocol.
Protocol deviations that would exclude participants 
from the PP population are defined in Se ction 4.1
(Protocol Deviations) and Appendix 1 : Protocol
Deviation Management and Definitions for Per 
Protocol Population ).Efficacy: Mayo only
PP + Completer s All partici pants in the PP population who also 
complete the study (Parts A, B and Follow -up)[1]Efficacy: Mayo only
Refer to Appendix 10: List of Data Displays which details the population used for each display.
[1] Completion of the study a s defined from the eCRF study conclusion page. 
Note: All data displays (Tables, Figures & Listings) will use the term “Subject” which reflects CDISC and GSK 
Data Display Standards terminology
4.1. Protocol Deviations
Important protocol deviations (including deviations related to study  inclusion/exclusion 
criteria, conduct of the trial, patient management or patient assessment) will be 
summari sed and listed . 2019N425893_00
CONFIDENTIA L
202152
14Important deviations which result in exclusion from the anal ysis population will also be 
summarised and listed. (Please refer to Appendix 1 : Protocol Deviation Management and 
Definitions for Per Protocol Population).
Protocol deviations will be tracked by  the study  team throughout the conduct of the study  
in accordance with the Proto col Deviation Management Plan Version 3, dated 14thJune
oData will be reviewed instream prior to unblinding and fre ezing the database to 
ensure all important deviations are captured and categori sed on the protocol 
deviations dataset. 
oThis dataset will be th e basis for the summaries and listings of protocol 
deviations.
A separate summary  and listing of all inclusion/exclusion criteria deviations will also be 
provided. This summary will be based on data as recorded on the inclusion/exclusion 
page of the eCRF.
5. CONSIDERA TIONS FOR D ATA ANALYSES AND DATA
HANDLING CONVENTIONS
5.1. Stud y Treatment & Sub -group Display  Descriptors
One subject was randomised to a BID regimen before the protocol was amended. Per 
instructions in the protocol, d ata will be summarised in tables and figures by treatment 
(GSK2982772 60mg or Placebo) irrespective of dosing regimen received (BID or TID) . 
Data will be listed pertreatment and dosi ng regimen received (BID or TID) . Some key 
safet y endpoints will be summarised by both randomised treatme nt and period treatment, 
details are provided in Appendix 9.
Should a participant receive the wrong medication at an y point during the study in error, 
that participant will be treated as having received GSK2982772 60mg TID for the 
duration of the study .   
Randomised Treatment Group Descriptions
RandAll NG Data Displays for Reporting 
Code Description Description in 
tables/non- PK figuresOrder 
in TF Description in 
Listings /PK figuresOrder in 
Listing
A GSK2982772 60mg BID 
(Double- blind)GSK2982772 60mg 2 GSK2982772 60mg 
BID3
C GSK2982772 60mg TID 
(Double- blind)GSK2982772 60mg 2 GSK2982772 60mg 
TID4
P Placebo B ID (Double -blind) Placebo 1 Placebo B ID 1
Q Placebo TID (Double -blind) Placebo 1 Placebo TID 2 2019N425893_00
CONFIDENTIA L
202152
15Period Treatment Group Descriptions
RandAll NG Data Displays for Reporting 
Code Description Description in tables Order 
in TF Description in 
ListingsOrder in 
Listing
A GSK2982772 60mg BID 
(Double- blind)GSK2982772 60mg 2 GSK2982772 60mg 
DB BID3
B GSK2982772 60mg B ID 
(Open- label)GSK2982772 60mg 2 GSK2982772 60mg 
OL BID5
C GSK2982772 60mg TID 
(Double- blind)GSK2982772 60mg 2 GSK2982772 60mg 
DB TID4
D GSK2982772 60mg TID 
(Open- label)GSK2982772 60mg 2 GSK2982772 60mg 
OL T ID6
P Placebo B ID (Double -blind) Placebo 1 Placebo DB B ID 1
Q Placebo TID (Double -blind) Placebo 1 Placebo DB TID 2
Treatment comparisons will be display ed as follows using the descriptors as specified:
GSK2982772 60mg vs Placebo.
5.2. Baseline Definition s
For all endpoints ( excep tas noted in baseline definitions) the baseline value will be the 
latest pre -dose assessment. Triplicate assessments a t a timepoint will be averaged. An 
additional period baseline will be determined for vital signs, ECGs and clinical labs.
Unless otherwise stated, if baseline data is missing ,no derivation will be performed and 
baseline will be set to missing.
For tables summarising from Day  43 (Part B), all data recorded on day  43 w illbe used as 
baseline and if this result is missing then there is no part B baseli ne.
Parameter Study Assessments Considered as Baseline Baseline Used 
in Data DisplayPeriod 
Baseline 
Used in Data 
DisplayScreening 
(-30)Screening ( -
7 to 30)Day 1 
(Pre-Dose)Day 1 
Primary: Safety 
Vital Signs[1,2] X X Day 1
(Pre-Dose)Day 43
12-Lead ECG[2] X[3] X Screening
or
Day 1 
(Pre-Dose)Day 43
Clinical Laboratory 
Values including CRP 
[2,4]X X Day 1
(Pre-Dose)Day 43 2019N425893_00
CONFIDENTIA L
202152
16Parameter Study Assessments Considered as Baseline Baseline Used 
in Data DisplayPeriod 
Baseline 
Used in Data 
DisplayScreening 
(-30)Screening ( -
7 to 30)Day 1 
(Pre-Dose)Day 1 
Columbia Suicide 
Severity Rating Scale 
(C-SSRS)X X Day 1 
(Pre-Dose)
Secondary
Mayo Score [5] X Scree ning
UCEIS X Screening
Modified Riley X Screening
Geboes Index X Screening
RHI X Screening
FCP X X Screening
Exploratory
Blood Sample: PK X Day 1 
Blood Sample: 
Exploratory 
Biomarkers, Target 
Engagement and 
mRNA Expression X Day 1 
(Pre-Dose)
Biopsy Tissue: PK, 
Inflammatory 
Biomarkers, mRNA 
Expression, Target 
Engagement and 
Pathway Marker X Screening
IBDQ X Day 1 
(Pre-Dose)
NOTES:
 Unless otherwise stated, the mean of replicate assessments at any given time point will be used as the value for that time point.
1: Vital sign measurements include Blood Pressure, Heart Rate, Respiratory Rate, and Body Temperature.
2: Where both screening and pre -dose are available, the value closest to first dose will be used.
3: ECG r ecordings will be performed in triplicate at screening. The mean of the triplicate measurements should be used.
4: Clinical Laboratory measurements include Clinical Chemistry (which includes CRP), Haematology and Urinalysis.
5: Includes Total Mayo, Partial Mayo and 3- domain Mayo Scores. 2019N425893_00
CONFIDENTIA L
202152
175.2.1. Derivations and Handling of Missing Baseline Data
Definition Reporting Details
Change from Baseline = Post- Dose Visit Value –Baseline
Log-Transformed Change from 
Baseline (Log eChange)=Log e(Visit) –log e(Baseline) .
NOTES :
 Unless otherwise specified, the bas eline definitions specified in S ection 5.2.Baseline Definitions will be used 
for derivations for endpoints / parameters . 
 Unless otherwise stated, if baseline data is missing no deri vation will be performed and will be set to missing.
 The baseline definition will be footnoted on all the change from baseline displays. 
5.3. Multicentre Studies
There are no planned adjustments for multiple centres or regions due to the size of the 
study . Enrolment will be presented b y country . For all other analy ses, all sites, countries 
and regions will be pooled.
5.4. Examination of Covariates , Other Strata and Subgroups
There are no planned subgroup anal yses to be conducted on this study .
Category Details
Strata Not applicable for this study
Covariates Baseline measure will be included as a covariate
5.5. Multiple Comparisons and Multiplicity
Overall, no adjustments will be made for multiple comparisons or multiplicity  across 
different endpoints.
The process to reduce the false discovery  rate for the transcriptomic analyses of mRNA
expression is detailed in Section 10.1.3.1 . 
5.6. Other Considerations for Data A nalyses and Data Handling 
Conventions
Other considerations for data anal yses an d data handling conventions are outlined in the 
appendices:
Section Component
12.1 Appendix 1 : Protocol Deviation Management and Definitions for Per Protocol Population
12.2 Appendix 2 : Schedule of Activities
12.3 Appendix 3 : Assessment Windows
12.4 Appendix 4 : Study Phases and Treatment Emergent Adverse Events
12.5 Appendix 5 : Data Display Standards & Handling Conventions 2019N425893_00
CONFIDENTIA L
202152
18Section Component
12.6 Appendix 6 : Derived and Transformed Data
12.7 Appendix 7 : Reporting Standards for Missing Data
12.8 Appendix 8 : Values of Potential Clinical Importance
12.9 Appendix 9: Abbreviati ons & Trademarks
12.10 Appendix 10: List of Data Displays
12.11 Appendix 11: Example Mock Shells for Data Displays
12.12 Appendix 12 : NONMEM datafile specification
6. STUDY POPULA TION ANALYSES
6.1. Overview of Planned Stud y Population Analyses
Study  population anal yses including anal yses of participant ’sdisposition, protocol 
deviations, demographic and baseline characteristics, prior and concomitant medications, 
and exposure and treatment c ompliance will be based on GSK C ore Data Standards.  
Details of the planned display sare presented in Table 2below and  Appendix 10: List of 
Data Display s.
The study  population analy ses will be based on the Safet y population, unless otherwise 
specified. 
6.1.1. Study Population Summary  Measure
Population analy ses will be presented (summarised in tables and listed) by  randomised 
treatment group onl y. 
Table 2 Overview of Planned Study  Populati on A nalyses
Endpoint / Parameter / Display Type Data Displays Generated
Table Figure Listing
Subject Disposition
Subject Disposition for the Subject Conclusion Record Y
Treatment Status and Reasons for Discontinuation of Study 
TreatmentY Y
Screen Status and Reason for Screen Failure Y Y
Subjects by Country and Site ID Y
Reasons for Subject Withdrawal Y
Subjects for Whom the Treatment Blind was Broken Y
Planned and Actual Treatments Y
Protocol Deviations
Important Protocol Deviations Y Y
Subjects with Inclusion/Exclusion Criteria Deviations Y 2019N425893_00
CONFIDENTIA L
202152
19Endpoint / Parameter / Display Type Data Displays Generated
Table Figure Listing
Populations Analysed
Study Populations Y
Exclusion from Any Population Y Y
Demographic and Baseline Characteristics
Demographic Characteristics Y Y
Age Ranges Y
Race and Racial Combinations Y Y [1]
Ulcerative Colitis Baseline Characteristics[2] Y Y
Prior/Current Medical Conditions and Concomitant Medications[3]
Medical Conditions Y Y
Concomitant Medications[4] Y Y
Cardiovascular Risk Factors Y Y
Exposure and Treat ment Compliance
Exposure to Study Treatment Y Y
Study Drug Accountability Y
NOTES:
 Y = Yes display generated.
1:Listing of race.
2:Baseline characteristics including :Baseline Mucosal Appearance at Endoscopy Mayo Subscore , Baseline Total 
Mayo Sco re,Baseline Partial Mayo Score, Baseline 3 -domain Mayo Score, Baseline UCEIS T otal Score, Baseline 
Modified Riley Scale , Baseline FCP, Baseline FCP category ,Baseline concomitant medications for UC
(Glucocorticoids only, Immunosuppressants only, Glucocor ticoids and immunosuppressants, No glucocorticoids or 
immunosuppressants) ,Baseline Prednisone dose, Family History of Premature Coronary Artery D isease and History of 
Tobacco U se.
3:Separate summaries for Current and P ast Medical C onditions/C ardiovascula rRisk F actors /Concomitant Medications .
4: The ingredients of c oncomitant medications will be reviewed by the clinical and medical team to determine baseline 
use of Glucocorticoids, Immunosuppressants and Prednisone . 2019N425893_00
CONFIDENTIA L
202152
207. SAFETY ANAL YSES
The safet y analyses will be based on the Safet y population, unless otherwise specified.
7.1. Adverse Events A nalyses
Adverse events analy sesincluding the anal ysis of adverse events (AEs), Serious (SAEs)
and other significant AEs will be based on GSK Core Data Standards. The detai ls of the 
planned display s are provided inTable 3 below and Appendix 12: L ist of Data Display s.
7.1.1. Adverse Event Summary  Measures
AEdata will be summarised in tables and figures by  the following : 
Part A by randomised treatment;
Parts A, B and follow -up by randomised t reatment ; 
Parts A, Band follow -upby period treatment (i.e. treatment participant actually  
received). 
AE data will be presented in data listing s by the following: 
Parts A, B and follow -up by period treatment (i.e. treatment participant actually  
received). 
Table 3 Overview of Planned Adverse Event Analyses
Endpoint / Parameter/ Display Type Absolute
Summary Individual
T F L
Adverse Events (AEs)
All AE by Maximu m Intensity by SOC and PT Y
All Drug -Related AEs by Maximum Intensity by SOC and PT Y
Common ( >=10 %) AEs / Drug -Related AEs by Overall Frequency Y Y [1]
Common (>=10 %) Non- serious AEs by SOC and P T(Number of Subjects and 
Occurrences)Y
All AEs Y Y
Subject Numbers for Individual AEs Y
Relationship Between AE SOCs, PT & Verbatim Text Y
Serious and Other Significant AEs
Serious AEs by SOC and PT (Number of Subjects and Occurrences) Y
Fatal Serious AEs Y
Non-Fatal Serious AEs Y
AEs Leading to Permanent Discontinuation of Study Treatment or Withdrawal 
from Study Y Y
Reasons for Considering as a Serious AE Y
Possible Suicidality -Related AE ( PSRAE ) Y 2019N425893_00
CONFIDENTIA L
202152
21NOTES:
 T = Table, F = Figures, L = Listings, Y = Yes display generated, SOC = System Organ Class, PT = Preferred 
Term.
 Summary = Represents TF related to any summaries (i.e. descriptive statistics) of the observed raw data.
 Individual = Represents L related to any displays of individual participant observed raw data.
1:Plot of co mmon AEs and relative risk will be generated.
7.2. Clinical Laboratory  Analyses
Laboratory  evaluations including the anal yses of Chemistry  laboratory  tests, Hematology  
laboratory  tests, Urinal ysis, and liver function tests will be based on GSK C ore Data 
Standar ds. Table 4 provides an overview of the planned analy ses with further detail being 
presented in Appendix 10: List of Data Display s.
7.2.1. Clinical Laboratory  Summary  Measures
Clinical L aboratory  data will be summar ised in tables and figures b y the following: 
Parts A, B and Follow -up by randomised treatment;
Parts A, B and Follow -up by period treatment (i.e. treatment participant actually  
received). 
Clinical L aboratory  data will be presented in data listings by  the following:  
Parts A and B and follow -up by  period treatment (i.e. treatment participant actuall y 
received). 
Table 4 Overview of Planned Clinical Laboratory  Analyses
Endpoint / Parameter/ Display Type Absolute Change from BL
Summary Individual Summary Individual
T F L T F L
Chemistry
Chemistry Results Y
Chemistry Lipids Results [1] Y[2]
Worst Case Chemistry Results Relative to PCI Criteria 
Post- Baseline Relative to BaselineY
Worst Case Lipids Results R elative to NR Criteria Post -
Baseline Relative to Baseline [1] Y
Lipids Outside of the Normal Range [1] Y
Hematology
Hematology Results Y
Worst Case Hematology Results Relative to PCI Criteria 
Post- Baseline Relative to BaselineY 2019N425893_00
CONFIDENTIA L
202152
22Endpoint / Parameter/ Display Type Absolute Change from BL
Summary Individual Summary Individual
T F L T F L
Urinalysis
Urine Concentration Y
Worst Case Urinalysis Results (Discrete or Character 
Values) Post -Baseline Relative to BaselineY
Hepatobiliary (Liver)
Liver Monitoring/Stopping Event Reporting Y
Hepatobiliary Laboratory Abnormalities Y
Medical Conditions for Subjects with Liver Stopping 
EventsY
Substance Use for Subjects with Liver Stopping Events Y
Scatter Plot of Maximum Versus Baseline for ALT Y
Scatter Plot of Maximum ALT Versus Maximum Total 
BilirubinY
All Laboratory[3]
All Laboratory Data for Subjects with Any Value of PCI Y
Laboratory Data with Character Results Y
NOTES:
 T = Table, F = Figures, L = Listings, Y = Yes display generated, PCI = Potential Clinical Importance
 Summary = Represents TF related to any summaries (i.e. descriptive statistics) of the observed raw data.
 Individual = Represents L related to any displays of individual participant observed raw data.
1: Lipids parameters = LDL Cholesterol, HDL Cholesterol, Total Cholest erol, Triglycerides and Cholesterol/HDL ratio
2: Percentage change sfrom baseline. 
3:Chemistry, Hematology and Urinalysis will be considered.
7.3. Other Safety  Analyses
The anal yses of non -laboratory  safet y test results including ECG sand vital signs will b e 
based on GSK Core Data Standards, unless otherwise specified. The details of the 
planned display s are presented in Table 5 below and Appendix 10: List of Data Display s.
7.3.1. Summary  Measures
Non-laboratory  safet y results will be summarised in tables and figures b y the following: 
Parts A, B and Follow -up by  randomised treatment; 
Parts A, B and Follow -up by  period treatment (i.e. treatment participant actually  
received). 
Non-laboratory  safety  results will be pre sented in data listings b y the following:  
Parts A and B and follow -up by  period treatment (i.e. treatment participant actuall y 
received).  2019N425893_00
CONFIDENTIA L
202152
23Table 5 Overview of Planned Other Safety  Analyses
Endpoint / Parameter/ Display Type Absolute Change from BL
Summary Individual Summary Individual
T F L T F L
ECG
ECG Findings Y
ECG Values1 Y
Maximum QTc Values Post -Baseline Relative to 
Baseline by Category1 Y
Maximum Increase in QTc Values Post -Baseline 
Relative to Base line by Category1 Y
All ECG Values for Subjects with Any Value of PCI1 Y
Vital Signs
Vital Signs Y
Worst Case Vital Signs Results by PCI Criteria Post-
Baseline Relative to BaselineY
All Vital Signs for Subjects with Any V alue of PCI Y
C-SSRS V4
C-SSRS Suicidal Ideation and Behaviour Data Y 
NOTES:
1. ECGs change from baseline are to be produced for change from screening (average triplicate) and change from 
baseline
 T = Table, F = Figures, L = Listings, Y = Yes disp lay generated, PCI = Potential Clinical Importance
 Summary = Represents TFL related to any summaries (i.e. descriptive statistics) of the observed raw data.
 Individual = Represents FL related to any displays of individual participant observed raw data.
7.4. Other Safety  Analyses
If any of the following events are recorded in the eCRF as a CV event during the stud y,
posthoc patient profile listings will be generated per IDSL and provided to the GCSP 
department:
Arrh ythmias, Congestive heart failure, Cerebrova scular events stroke (CVA) and 
Transient ischemic attack (TIA) , Deep vein thrombosis (DVT)/Pulmonary  
embolism (PE), My ocardial I nfarction/Unstable Angina, Peripheral arterial 
thromboembolism, Pulmonary  Hypertension, Revascularisation , Valvopathy . 2019N425893_00
CONFIDENTIA L
202152
248. EFFICACY
8.1. Efficacy  Endpoints
Table 6 below provides an overview of the planned efficacy anal yses, with full details of 
data display s being available in Appendix 10: List of Data Display s.  
Table 6 Overview of Planned Efficacy  Analyses
Endpoint Absolute Change from Baseline
Stats Analysis Summary Individual Stats Analysis Summary Individual
T F L[1]T F F L T F L[1] T F F L
Mayo –Endoscop y Respon se
Mucosal Appearance 
at Endoscopy Mayo 
Subscore Y Y
Proportion Achieving 
Mayo Endoscopy 
Remission C C C Y Y Y
Mayo –Clinical Response and Remission 
Proportion Achieving 
Mayo Clinical 
Response C C C Y Y Y
Proportion Achieving 
Mayo Clinical 
RemissionC C C Y Y Y
Proportion Achieving 
3-domain Mayo 
Clinical Response C C C Y Y Y
Proportion Achieving 
3-domain Mayo 
Clinical RemissionC C C Y Y Y
Mayo –Symptomatic Clinical Remission 
Total Y Y Y C C C Y Y Y
Partial Mayo Y Y Y C C C Y Y Y
3-domain Mayo Y Y Y C C C Y Y Y
UCEIS –Mucosal Healing 
UCEIS Total Score Y Y Y C C C Y Y Y
UCEIS –Remission 
Proportion Achieving 
UCEIS Remission C C C Y Y Y
Biomarkers of Disease Activity
CRP Y Y Y C C C Y Y Y
FCP [2] Y Y Y C C C Y Y Y
Histologic Disease Activity
Modified Riley Scale Y Y Y C C C Y Y Y
Geboes Index Total 
ScoreY Y Y C C C Y Y Y
RHI Total Score Y Y Y C C C Y Y Y 2019N425893_00
CONFIDENTIA L
202152
25Endpoint Absolute Change from Baseline
Stats Analysis Summary Individual Stats Analysis Summary Individual
T F L[1]T F F L T F L[1] T F F L
Quality of Life
IBDQ Domains [3] Y Y Y Y
IBDQ Total Score Y Y Y C C C Y Y Y
Subject Symptom Diary Cards
Diary Card [4]Y Y
NOTES:
T = Table, F = Figure, L = Listing, Y = Yes display generated, C = conditional 
Stats Analysis = Represents TFL related to any formal statistical analy ses (i.e. modelling) conducted.
Summary = Represents TFL related to any summaries (i.e. descriptive statistics) of the observed raw data.
Individual = Represents FL related to any displays of individual participant observed raw data.
1. Listing of the RAW SAS output from the statistical modelling. 
2. FCP will be log -transformed before determining change from baseline.
3. IBDQ domains: Bowel Symptoms, Systemic Systems, Emotional Function and Social Function. 
4. Data from diary cards will be transcribed into the eCRF f or the 5 days prior to the following visits: Screening, 
Day 15, Day 29, Day 43, Day 85 and EW.
8.1.1. Population of Interest 
Analyses of the May o will be based on the S afety , PP and PP + Completers populations 
respectivel y. 
All other efficacy  anal yses will be based on the Safet y Population only.
8.1.2. Statistical A nalyses / Methods
Details of the planned display s are provided in Appendix 10: List of Data Display s and 
will be based on GSK data standards and statistical principles.
All efficacy  data will be summarised for Parts A, B and Follow -up (if applicable) by 
randomised treatment. 
Unless otherwise specified, endpoints / variables defined will be summarised using 
descriptive statistics, graphically  presented (where appropriate) and listed.
8.1.2.1. Statistical Methodology  Specification
8.1.2.1.1 Continuous Endpoints
Secondary and Exploratory Endpoint(s)
Change from baseline in Total and 3-d omain Mayo Score at Day 43 pre -dose and Day 85.
Change from baseline in Partial Mayo Score at Day 15, Day 29, Da y 43 pre -dose and Day 85.
Change from baseline in UCEIS Total Score at Day 43 pre -dose and Day 85.
Change from baseline Modified Riley Scaleat Day 43 pre -dose and Day 85.
Change from baseline Geboes Index Total Score at Day 43 pre -dose and Day 85.
Change from baseline RHI Score at Day 43 pre -dose and Day 85.
Change from baseline in CRP at Day 43 pre -dose and Day 85.
Change from baseline in Log-transformed FCP at Day 15, Day 29, Day 43, Day 57, Day 71 and Day 85.
Change from baseline in IBDQ Total Score at Day 43 pre -dose and Day 85. 2019N425893_00
CONFIDENTIA L
202152
26Model Specification
Continuous e ndpoints will be statistically analyzed using a Mixed Models Repeated M easures (MMRM) 
approach. 
Terms fitted in the MMRM model will include:
oFixed Category                           : Treatment , Day, Treatment*Day
oFixed Continuous Covariates     : Baseline Score, baseline*Day
oRepeated Effect                         : Day
The Kenward and Roger method for approximating the denominator degrees of freedom and correcting 
for bias in the estimated var iance -covariance of the fixed effects will be used. 
An unstructured covariance structure for the R matrix will be used by specifying ‘type=UN’ on the 
REPEATED line with a subject=SUBJID option.
oIn the event that this model fails to converge, alternative c orrelation structures may be 
considered such as CS or AR(1). 
oAkaike's Information Criteria (AIC) will be used to assist with the selection of covariance 
structure.
Other covariates maybe explored, if deemed appropriate for sensitivity analyses.
Model Che cking & Diagnostics
MMRM m odel assumptions will be applied, but appropriate adjustments may be made based on the 
data.
Distributional assumptions underlying the MMRM model will be examined by obtaining a normal 
probability plot of the residuals and a plot of the residuals versus the fitted values (i.e. checking the 
normality assumption and constant variance assumption of the model respectively) to gain confidence 
that the model assumptions are reasonable. 
If there are any departures from the distributiona l assumptions, alternative models will be explored using 
appropriate transformed data.
Model Results Presentation -Untransformed
Point estimates and corresponding 95% confidence intervals will be constructed for the treatment 
differences (GSK2982772 60mg tid-Placebo), using the residual error from the repeated measures 
model.
Plots of LS means and 95% confidence intervals from the model will be generated for each treatment 
group by time.
For log -transformed data the adjusted back -transformed geometric means and CV will be presented.
Model Results Presentation -  Log transformed
Adjusted geometric means, the mean difference between each dose (test) and the placebo (reference) at 
each timepoint and associated 95% confidence interval will be constructed using the residual variance
The treatment ratios and 95% CI will be calculated by back -transforming the difference between the least 
square means and associated 95% CI
Sensitivity and Supportive Statistical Analyses
Non-parametric analyses may be conducte d if the normality assumption does not hold.
Analyses using different covariance structures may be explored if the unstructured covariance matrix 
does not converge.
8.1.2.1.2 Binary  Endpoints
Secondary and Exploratory Endpoint(s)
Proportion of participa nts achieving a Mayo endos copy remission at Day 43 pre -dose and Day 85.
Proportion of participant sachieving Mayo clinical response and 3 -domain Mayo clinical response at Day 
43 pre- dose and Day 85. 2019N425893_00
CONFIDENTIA L
202152
27Proportion of participants achieving Mayo clinical remiss ion and 3 -domain Mayo clinical remission at Day 
43 pre- dose and Day 85.
Proportion of participant sachieving an UCEIS remission at Day 43 pre -dose and Day 85.
Model Specification
Binary efficacy endpoints will be statistically analysed using a Generalise d Estimating Equations (GEE) 
model.
GEE modelling will only be performed if at least 30% response rate atDay 85 for any one treatment 
group.
The model will be fitted using an unstructured covariance structure of the correlated responses.
Terms fitted in the GEE model will include:
Fixed Categorical : Treatment group, Visit, Treatment group * Visit Interaction
Repeated : Visit
Model Results Presentation
Binary endpoints will be summarised using counts and proportions of participant sachieving a re sponse by 
treatment group.
Point estimates and corresponding 95% confidence intervals will be constructed using contrasts for the 
treatment group by visit interaction.
Plots of the point estimates and 95% confidence intervals from the model will be generat ed for each 
treatment group by time.
If a minimum 30% response rate at Day 85 for any one treatment group is not achi eved, the display should 
be created with ‘Insufficient data to produce GEE analysis’ printed in the main body of the display.
8.2. Exploratory Efficacy  Analyses
8.2.1. Responder A cross Endpoints 
For appraisal of trends across secondary  efficacy  endpoints, a nine -panel plotforeach 
participant with a single panel for each of the following efficacy  endpoints will be 
produced:  
Mayo Endoscopy  Remission
UCEI S Total Score,
FCP,
CRP,
Modified Riley Scale Total Score
Geboes Index Total Score, 
Total May o Score, 
Partial May o Score
3-domain Mayo Score.
8.2.2. Probabilities of Success 
Probabilities of success may be determined, based on the data observed in the st udy, 
where the definition of success will be dependent on the endpoint. For example, what is 
the probability  that we would observe a certain proportion of May o Endoscopic 
Remission (0 or 1) (i.e., comparatory  rate), based on the data that we have observed in 
thisstudy . 2019N425893_00
CONFIDENTIA L
202152
28A Bay esian approach will be employ ed to determine a 95% credible confidence interval 
around the observed probability  of success with a flat Beta (1, 1) prior. Any such 
analyses will be done b y GSK II Clinical Statistics after unblinding of the interim data 
and thus will be deemed post -hoc.
8.3. Exploratory  Pharmacodynamic / Efficacy  Analyses
If deemed appropriate, the relationship between the biopsy  biomarkers and efficacy  
endpoints will be explored further using multivariate statistical metho ds and/or Bay esian 
methodology  as recommended by  the GSK PCPS Experimental Medicine working group. 
The consistency  in the changes over time between the endpoints will also be assessed.  
Any such anal yses will be defined after unblinding of the interim data and thus will be 
deemed post -hoc.
9. PHA RMACOKINETIC A NALYSES
9.1. Pharmacokinetic Analy ses
9.1.1. Endpoint / Variables
9.1.1.1. Drug Concentration Measures
PK plasma and biopsy tissue Concentration data for GSK2982772 will be summarised 
and listed, no statistical analy sis will be conducted. Summary  statistics of GSK2982772 
concentration by  Day  (1, 43, and 85) and nominal blood sampling time will be 
determined. PK blood samples are taken pre -dose on Day  43 and post -dose on Day s 1 
and Day  43 at the following time points: 1, 2, 4, and 6 hours and trough on Day  85 or 
Early Withdrawal.
PK data will be summarised for Parts A andB by randomised treatment. 
Refer to Appendix 5 : Data Display Standards & Handling Conventions (Section 12.5.3
Reporting Standards for Pharmacokinetic) .
Table 7 Overview of Planned Pharmacokinetic A nalyses
Endpoints Untransformed Log-transformed 
Summary Individual Summary Individual
T F F L T F F L
Pharmacokinetic 
Plasma Drug concentration Y Y[1][2] Y[1] Y
Biopsy Tissue Drug 
concentration Y Y[1][2] Y[1] Y 2019N425893_00
CONFIDENTIA L
202152
29NOTES:
 T = Table, F = Figure, L = Listings, Y = Display generated.
 Summary = represents TF related to any summaries (i.e. descriptive statistics) of the observed raw data.
 Individual = represents FL related to any displays of individual participant observed raw data.  
1:  Linear and Semi -Log plots will be created on the same display.
2: Separate Mean (± SE) and Median plots will be generated.
Since the half -life of GSK2982772 is short (2 -3h), the duration of time between the Day  
43 clinic visit and the usual dosing time may  result in the reported “pre- dose” 
concentration being lower than the true “pre -dose” or trough concentration (e.g. if the 
usual dose time was 7am and the clinic visit was 10am the “pre-dose” sample collected at 
10 am would be approximately  ½ that of the true “trough” concentration assuming a 3 
hour half -life).  Therefore, the predicted “trough” concentration will be calculated usin g 
the following equation -
where
Ctrough = predicted trough concentration prior to usual dosing time 
Cpredose = observed “pre -dose” concentration collected at the clinic 
t = time in hours between pre-dose blood sample collection and time of dosing 
(assumed to be 7am) 
ke = elimination rate constant (0.693/ t½), (t½ assumed to be 2.5h) 
9.1.2. Population of Interest 
The PKanalyses will be based on the Pharmacokinetic population, unless otherwise 
specified.
9.2. Population PK A nalyses
GSK2982772 plasma concentratio ns from this study  may  be included in a cross -study  
population pharmacokinetic (Pop PK) analysis. If deemed appropriate to conduct a Pop
PK analy sis,a NONMEM datafile will be generated. The details for the dataset 
specifications are provided in Appendix 12. 
9.3. Pharmacokinetic /Pharmacody namic Anal yses
The relationship between GSK2982772 predicted trough concentration and the following 
variables will be explored graphicall y: 
Target engagement from the corresponding blood/biopsy tissue sample ;
Change from baseline in continuous efficacy  endpoints (Total Mayo Score, Partial 
Mayo Score , 3-domain Mayo Score , UCEIS Total Score, Modified Riley  Scale
Score, Geboes Index Total Score, RHI Score, CRP and FCP.  2019N425893_00
CONFIDENTIA L
202152
30Box plot of GSK2982772 concentrati ons in participant s not achieving a May o Endoscopy  
Remission and participants achieving a May o Endoscopy  Remission.
10. BIOM ARKER ANALYSES
10.1. Biomarker/Target Engagement/Pathway  Engagement/ 
Transcriptomics A nalyses
10.1.1. Endpoint / Variables
Table 8 Overview of Planned A nalyses
Endpoint Absolute Change from Baseline
Stats Analysis Summary Individual Stats Analysis Summary Individual
T F L T F F L T F L T F F L
Exploratory Biomarkers
Inflammatory 
biomarkers in biopsy 
tissue1Y Y Y Y Y Y Y Y
Pathway and Target Engagement
Pathway and t arget 
engagement in blood2Y Y Y Y Y3Y
Pathwa y and target 
engagement in biopsy 
tissue2Y Y Y Y Y Y
Transcriptomics 
mRNA 
expression from 
blood[3][4]Y Y Y Y Y Y
mRNA expres sion from 
biopsy tissue[3][4] Y Y Y Y Y Y
NOTES:
 T = Table, F = Figure, L = Listing, Y = Yes display generated.
 Stats Analysis = Represents TFL related to any formal statistical analyses (i.e. modelling) conducted.
 Summary = Represents TF related to any summaries (i.e. descriptive statistics) of the observed raw data.
 Individual = Represents FL related to any displays of individual participant observed raw data
1: Markers including but not limited to:  IL -1, IL-6, IL-8, MMP -3, TNFα and IFNy 
2: TEAR1, phosp horylated or total RIP1, MLKL, and RIP3, cleaved and total caspase 3 and caspase 8 signatures 
in blood and biopsy tissue if sample quantity and data allow.
3:mRNA expression of inflammatory gene transcripts including but not limited to: IL -4, IL-10, IL -17, IL -21, IL -22, 
IL-23, TNF and IFNγ .
4: Data to be analysed by the GSK II Statistics and Programming Team Post-SAC.
Scatter plots of Target Engagement and blood/biopsy  tissue biomarkers for Day  43 and 
Day 85 will also be produced.   2019N425893_00
CONFIDENTIA L
202152
31If deemed appropriate, the relationship between Target Engagement and the blood/biopsy  
tissue biomarkers will be explored further using multivariate statistical analy ses. The 
consistency  in the changes over time between the endpoints will also be assessed.  An y 
such anal yses will be defined after unblinding of the data and thus deemed post -hoc.
10.1.2. Population of Interest
The pharmacod ynamic/b iomarker analyses will be based on the Safetypopulation, unless 
otherwise specified .
10.1.3. Statistical A nalyses / Methods
Details of the planned display s are provided in Appendix 10: List of Data Display s and 
will be based on GSK Data Standards and statistical principles.
Unless otherwise specified, endpoints / variables defined in Section 10.1.1 will be 
summarised using descriptive statistics, graphically presented (where appropriate) and 
listed.
Biomarker data will be summarised for Parts A and B combined by  randomised 
treatment. 
10.1.3.1. Statistical Methodology  Specification
Exploratory Inflammatory Biomarkers
Endpoints
Change from baseline on log transformed inflammatory biomarkers in biopsy tissue on Day 43 pre -dose 
and Day 85: Log eChange = Log e(Visit) – log e(Baseline).
Markers include but not limited to : IL-1, IL-6, IL- 8, MMP -3, TNFα and IFNy .
Model Specification
Endpoints will be statistically analyzed using a mixed model repeated measures (MMRM) approach. 
Terms fitted in the MMRM model will include:
oFixed Category                           : Treatme nt, Day, Treatment*Day
oFixed Continuous Covariates     : Baseline Score, baseline*Day
oRepeated Effect                          : Day
The Kenward and Roger method for approximating the denominator degrees of freedom and correcting 
for bias in the estimated variance -covariance of the fixed effects will be used. 
An unstructured covariance structure for the R matrix will be used by specifying ‘type=UN’ on the 
REPEATED line with a subject=SUBJID option.
Model Checking & Diagnostics
For the MMRM, model assump tions will be applied, but appropriate adjustments may be applied based 
on the data.
In the unlikely circumstance that there are convergence problems with the MMRM analysis, this will be 
explored. For example, the SCORING=4 option could be used in the MIXE D statement, which makes 
SAS use Fisher scoring for the first 4 iterations. If the convergence problem cannot be resolved, the 
unstructured covariance matrix will be replaced by ANTE ( 1) covariance structure in combination with a  2019N425893_00
CONFIDENTIA L
202152
32random participant effect.
oIfthis model fails to converge, alternative correlation structures may be considered such 
as CS or AR (1). 
oAkaike's Information Criteria (AIC) will be used to assist with the selection of covariance 
structure.
Distributional assumptions underlying the m odel used for analysis will be examined by obtaining a 
normal probability plot of the residuals and a plot of the residuals versus the fitted values (i.e. checking 
the normality assumption and constant variance assumption of the model respectively) to gain
confidence that the model assumptions are reasonable. 
If there are any departures from the distributional assumptions, alternative models will be explored 
using appropriate transformed data.
Presentation of results
Adjusted geometric means, the mean di fference between each dose (test) and the placebo (reference) 
at each timepoint and associated 95% confidence interval will be constructed using the residual 
variance.
The treatment ratios and 95% CI will be calculated by back -transforming the difference b etween the 
least square means and associated 95% CI.
Percentage change from baseline at each timepoint will be calculated from the adjusted geometric 
means using the formula 100% x (exp (adj mean) -1).
Pathway and Target Engagement 
Endpoints
Log Rat io = Log (free TEAR1) –log (total TEAR1). 
Model Specification
A mixed effect model will be fitted with randomised treatment, time (i.e. planned relative time) and 
randomised treatment * time as a fixed effect and participant as a random effect.  Baseli ne log ratio will 
be fitted as a continuous covariate along with Baseline log ratio* time.
The Kenward and Roger method for approximating the denominator degrees of freedom and correcting 
for bias in the estimated variance -covariance of the fixed effects w ill be used. 
An unstructured covariance structure for the R matrix will be used by specifying ‘type=UN’ on the 
REPEATED line with a subject=SUBJID option.
Model Checking
For the MMRM, model assumptions will be applied, but appropriate adjustments may be applied based 
on the data.
In the unlikely circumstance that there are convergence problems with the MMRM analysis, this will be 
explored. For example, the SCORING=4 option could be used in the MIXED statement, which makes 
SAS use Fisher scoring for the first 4 iterations. If the convergence problem cannot be resolved, the 
unstructured covariance matrix will be replaced by ANTE ( 1) covariance structure in combination with a 
random participant effect.
Ifthis model fails to converge, alternative correlation structures may be considered such as CSH or CS. 
Distributional assumptions underlying the model used for analysis will be examined by obtaining a 
normal probability plot of the residuals and a plot of the residuals versus the fitted values (i.e. checking
the normality assumption and constant variance assumption of the model respectively) to gain 
confidence that the model assumptions are reasonable. 
If there are any departures from the distributional assumptions, alternative models will be explored 
using appropriate transformed data. 2019N425893_00
CONFIDENTIA L
202152
33Pathway and Target Engagement 
Presentation of Results
Adjusted geometric means, the mean difference between each dose (test) and the placebo (reference) 
at each timepoint and associated 95% confidence interval will be constructed using the residual 
variance.
The treatment ratios and 95% CI will be calculated by back -transforming the difference between the 
least square means and associated 95% CI.
Percentage target engagement at each timepoint will be calculated from the adjusted geometric means 
using the formula :100% x (exp (ln (v2 / v1) + 1) 
percentage target engagement = (1 –engagement ratio) * 100.
Transcriptomics –Fold Change Analysis
The log 2normalised copy numbers (also referred to as log2(intensity)) received from the normalised 
process will be listed and summarised appropriately by randomised treatment.
As the data will be log 2transformed prior to the analysis, the randomised treatment effects will be 
expressed as ratios after back transformation to the original scale. These ratios can be c onverted from 
randomised treatment ratios to fold change values as follows:  
If ratio ≥ 0 then fold change = ratio
If ratio <0 then fold change = - 1/ratio
Endpoint(s)
Log2(intensity) mRNA expression of inflammatory gene transcripts 
Model Specification
Endpoints will be statistically analyzed using a linear repeated measure mixed effects model. 
Terms fitted in the linear repeated measures mixed effects model will include:
oFixed Cat egory                          : Treatment, Visit, Treatment * Visit
oRandom Effect                           : Participant
Model Checking & Diagnostics
Model assumptions will be applied, but appropriate adjustments may be applied based on the data.
In the unlikely circumstance that there are convergence problems with the an alysis, this will be 
explored. 
If this model fails to converge, alternative correlation structures may be considered such as CSH or CS. 
Distributional assumptions underlying the model used for analysis will be examined by obtaining a 
normal probability p lot of the residuals and a plot of the residuals versus the fitted values (i.e. checking 
the normality assumption and constant variance assumption of the model respectively) to gain 
confidence that the model assumptions are reasonable. 
If there are any de partures from the distributional assumptions, alternative models will be explored 
using appropriate transformed data.
Presentation of Results
For each probeset analysed adjusted means with corresponding 95% CI and fold changes with 
corresponding 95% CI’s can be outputted. The fold change is derived from the ratio of the back -
transformed estimate of the difference between adjusted means.
Plots of LS means and 95% confidence intervals from the model will be generated for each treatment 
by time. Additionally , plots of differences and 95% confidence intervals for the comparison between the 
treatment groups will be generated.
For each comparison subsets of probesets will be identified based on an appropriate fold -change, for 
example, fold changes >1.5 or <- 1.5.The proportion of probesets with fold changes >1.5 or < -1.5 will  2019N425893_00
CONFIDENTIA L
202152
34Transcriptomics –Fold Change Analysis
be summarised in a frequency table.
Exploratory graphical reporting on the back -transformed scale can include:
Log 2(intensity) plotted against time point separately for individual participa nts, grouped by 
randomised treatment group
Adjusted mean intensity and 95 CI%  plotted by treatment group and time point.
Transcriptomics -MicroArray RNA Analysis
MicroArray RNA will be extracted and hybridised using a balanced batch design by Epistem. An 
appropriate microarray platform will be determined at the time of hybridisation, to allow for 
improvements in technology. The quality of the data will be assessed and then normalised using 
appropriate methodologies and software.
Microarray mRNA data wi llbe normalised using gcRMA or RMA in Array Studio v5.0 or later. After 
normalisation, the data will be quality assessed and any samples deemed as QC fails will be excluded 
from any further analysis. This quality assessment will involve looking for outlyi ng signals in both the 
normalised expression data and the MAS5 QC metrics generated from each sample. If any samples 
are excluded, the remaining data will be re -normalised. The output from the normalisation will be log 2
transformed mRNA intensity data (me asured in arbitrary units).
Microarray data consists of expression values (log 2-transformed) derived from individual probesets 
designed against coding regions of individual genes. More than one probeset can exist per gene. This 
analysis will be conducted a t the probeset level.
To identify the most robustly expressed probesets, the data can be filtered to remove low intensity 
probesets, low quality and control probe sets prior to analysis. This could be done simply by excluding 
all probesets where all observ ations are <6 (on the log 2scale). Note it has been observed empirically 
that when you get below 100 (6.6 on the log 2scale) you are into the noise of the assay. Other more 
stringent methods of filtering the data could be used. In total, there are 53,617 p robesets that could be 
analysed. 
To compare the expression value for each probeset, the following linear repeated measures mixed 
effects model will be fitted to each probeset that passes any pre -filtering, with log 2(intensity) as the 
response variable. R andomised Treatment by visit, randomised treatment and visit will be fitted as fixed 
effects and participant as a random effect. Example SAS code is given below: 
proc mixed data=data; 
ods output covparms=cov lsmeans=lse estimates=Compare;
class subjid treatment visit; 
model lgintensity= treatment visit treatment*visit /ddfm=kr;
repeated visit / subject=subjid type=un;  
lsmeans treatment*visit / diff cl alpha=0.05; 
run; 
For each probeset analysed adjusted means with corresponding 95% CI and fold changes with 
corresponding 95% CI’s can be outputted. The fold change is derived from the ratio of the back -
transformed estimate of the difference between adjusted means. 2019N425893_00
CONFIDENTIA L
202152
35Transcriptomics -MicroArray RNA Analysis
Where appropriate, particularly with microarray data, multiple testing will be considered using the 
Benjamini -Hochberg correction (Benjamini, Y; J Royal Stat Soc 1995;57:289 -300) to calculate FDR 
adjusted p -values. Proc Multtest incorporating the FDR adjusted p -value option is SAS is used to 
convert the raw p- values from the proc mixed code abo ve into the FDR adjusted p -values based on the 
Benjamini -Hochberg correction. Example code to generate the FDR adjusted p -values is given below:
data pvalues (keep = probsid label probt rename=(probt=raw_p));
     set compare;
run;
proc multtest pdata=pvalues fdr out=FDRres noprint;
run;
Where the FDRes dataset will include the following columns:
p-values
Test Raw False Discovery Rate
1 0.2828 0.9243
2 0.9437 0.9437
3 0.0350 0.6305
etc.
Appropriate outputs will be created containing all the results for the relevant comparisons for all 
analysed probesets. A summary may be generated, including probeset ID, gene ID, time point, adjusted 
means with corresponding 95% CI for each randomised treatment group, Benjamini -Hochberg FDR 
adjusted p -value and fold changes corresponding 95% CI from each comparison. Note that probeset ID 
is required if there is more than one probeset per gene.  
For each comparison subsets of probesets will be identified based on an appropriate fold -change, for 
example, fold changes >1.5 or < -1.5. The proportion of probesets with fold changes >1.5 or <- 1.5 will 
be summarised in a frequency table.
The outputs should be reviewed by the study team and the pre -agreed subset of biologically relevant 
probesets will be reported within the CSR. If based on the fold -changes observed other probesets, 
which were not pre -specified in the RAP, are deemed relevant then these should be interpreted with 
caution. 
Exploratory graphical reporting on the back -transformed scale can include:
Log 2(intensit y) plotted against time point separately for individual participants , grouped by 
randomised treatment group
Adjusted mean intensity and 95 CI%  plotted by randomised treatment group and time point. 2019N425893_00
CONFIDENTIA L
202152
36Transcriptomics –Microarray Percentage Inhibition Analy sis
The log 2normalised data is back transformed and the percentage inhibition is derived on a participant
level on the back transformed data for each probeset. The percentage inhibition will be determined for 
each probeset per participant , where it is de fined as the reduction from baseline. For example: 
Day X –baseline = -40% would be a 40% reduction (i.e. - 40% change from baseline) which in turn is 
defined as a 40% inhibition. So, the percentage inhibition would be calculated as:
[ (Day x –Baseline) / Baseline] * -100 = % inhibition
A subset of probesets may be identified and individual participant mRNA intensities and percentage 
inhibitions may be listed, summarised and plotted appropriately for each selected probeset. The 
selected probesets will be s tatistically analysed appropriately, and the output from the mixed effects 
model summarised. The probeset, gene or gene description will be included in the outputs.
To compare the percentage inhibition for each selected probeset, the following linear repea ted 
measures mixed effects model will be fitted to each selected probeset, with percentage inhibition as the 
response variable. Randomised Treatment by visit, randomised treatment and visit will be fitted as fixed 
effects and participant as a random effect . Example SAS code is given below :
proc mixed data=data; 
class subjid treatment visit; 
model perinhibit= treatment visit treatment*visit /ddfm=kr;
repeated visit / subject=subjid type=un;  
lsmeans treatment*visit / diff cl alpha= 0.05; 
run; 
11. REFERENC ES
Guyatt, G, Mitchell A , Irvine E J , Singer J ,Williams N, G oodacre R , and T omkins C ;
A New Measure of Health Status for Clinical Trials in I nflammatory  Bowel Disease . 
Gastroenterology . 1989; 96:804-10 2019N425893_00
CONFIDENTIA L
202152
3712. APPENDICES
12.1. Appendix 1: Protocol Deviation Management and Definitions 
for Per Protocol Population
12.1.1. Exclusions from Per Protocol Population
A participant meeting any  of the following criteria will be excluded from the Per Protocol 
population:
Number Exclusion Description
01Inclusion # 9 –Informed Consent: Informed Consent not available at site or Patient 
did not sign or date
02 Inclusion #2 – Eligibility: Other medical conditions
03 Inclusion #3 – Eligibility: Confirmed diagnosis of UC
04 Inclusion #4 – Eligibility: Total Mayo score and endoscopy subscore
05 Inclusion #5 – Eligibility: Stable concurrent medication
06 Inclusion #6 – Eligibility: Prior treatment
07 Incorrect randomisation or study unblinding procedures
A participant meeting any of the following criteria will be reviewed for exclusion fr om 
the Per Protocol population:
Number Exclusion Description
08 Exclusion #17 –Concomitant Medication 2019N425893_00
CONFIDENTIA L
202152
3812.2. Appendix 2: Schedule of A ctivities
12.2.1. Protocol Defined Schedule of Events
Procedures
Screening (-30)
Screening (-7 to -30)Treatment Period18
Early 
Withdrawal
19
Follow Up 
(3)20
PART A PART BDay 1 
Day 8 ( 3)
Day 15 ( 3)
Day 22 ( 3)
Day 29 ( 3)
Day 36 ( 3)
Day 43 ( 3)
(week 6)
Day 50 ( 3)
Day 57 ( 3)
Day 64 ( 3)
Day 71 ( 3)
Day 78 ( 3)
Day 85 (+2)
(week 12)
Site Visit X X X X X X X X X X X
Phone call X X X X X X
General/Safety Assessments and Procedures
Informed Consent X
Subject Demography X
Full medical history1 X
Inclusion/Exclusion Criteria X
Full physical exam2 X X X X
Brief physical exam X4 X X X4 X X
Vital signs (BP, HR, RR, 
temperature)X X4 X X X4 X X X X X
12-lead ECG3 X X4 X X X4 X X X X X
Concomitant medication review & 
AE reporting/SAEs5X--------- -----------------------------------------------------------------------------------------------------
PROs/Questionnaires/Disease Assessments and Procedures
Columbia Suicide Severity Rating X X4 X4 X X 
 
 2019N425893_00
CONFIDENTIA L
202152
39Procedures
Screening (-30)
Screening (-7 to -30)Treatment Period18
Early 
Withdrawal
19
Follow Up 
(3)20
PART A PART BDay 1 
Day 8 ( 3)
Day 15 ( 3)
Day 22 ( 3)
Day 29 ( 3)
Day 36 ( 3)
Day 43 ( 3)
(week 6)
Day 50 ( 3)
Day 57 ( 3)
Day 64 ( 3)
Day 71 ( 3)
Day 78 ( 3)
Day 85 (+2)
(week 12)
Scale (C -SSRS)
IBDQ6 X4 X4X X
UCEIS, Modified Riley, Geboes 
IndexX------- X7 X4 X X
Mayo Score (including 
sigmoidoscopy and biopsy)X-----X7 X4, 8 X X9
Partial Mayo Score X-----X7 X X X4 X X
Study Treatment
Randomisation X
Study medication (three times 
daily)10X---------------------------------------- XX--------------------------------------- X11
Dispensing of study medication X X X
Dispensing of diary cards X X X X X X
Collection of diary cards X X X X X X
Laboratory (Safety) Assessments and Procedures
TB, HIV, Hep B, Hep C Ab, C. 
Difficile toxin X
FSH & estradiol (if applicable) X
Serum pregnancy test (WCBP 
only)X 
 
 2019N425893_00
CONFIDENTIA L
202152
40Procedures
Screening (-30)
Screening (-7 to -30)Treatment Period18
Early 
Withdrawal
19
Follow Up 
(3)20
PART A PART BDay 1 
Day 8 ( 3)
Day 15 ( 3)
Day 22 ( 3)
Day 29 ( 3)
Day 36 ( 3)
Day 43 ( 3)
(week 6)
Day 50 ( 3)
Day 57 ( 3)
Day 64 ( 3)
Day 71 ( 3)
Day 78 ( 3)
Day 85 (+2)
(week 12)
Urine pregnancy test (WCBP 
only)12 X4X X X4 X X X X X
Haematology, chemistry, 
urinalysis X X4 X X13 X4 X13 X13 X X X
Faecal calprotectin14 X X X X X X X X X
Blood sample for exploratory 
biomarkers and TE15X4 X4 X X
PK blood sample s GSK298277216 X X4 X X
Biopsies for PK, inflammatory 
biomarkers, mRNA, TE & pathway 
marker analysisX------- X7 X4 X X8
Pharmacogenetic sample (PGx)17 X
Footnotes:
1. Full medical history (includes past and current conditions, medication history, substance usage, and family history of premature CV disease).
2. Full physical exam (includes height/weight at screening, height not measured at later time points).
3. Triplicate ECG to be performed at screening only and if stopp ing criteria are met .
4. Pre-dose.  
5. Any SAEs assessed as related to study participation (e.g., protocol -mandated procedures, invasive tests, or change in existing therapy) or related to a GSK product will be 
recorded from the time a participant consents to p articipate in the study up to and including any follow -up.  AEs will be collected from the start of Study Treatment until the follow -
up contact.
6. PRO assessments should be conducted before any tests, procedures or assessments to avoid influencing the partic ipants’ perception. 
 
 2019N425893_00
CONFIDENTIA L
202152
417. Sigmoidoscopy may be performed at any time during the screening window as an additional visit (if required) up to Day -7 in order for central reading confirmation of Mayo Score 
for inclusion.  If a shorter window is required (e.g., with in Day -3 to Day -7), this will be permitted as long as it has been confirmed with the sponsor and central reader that results 
of the Mayo endoscopy score will be available before end of screening window.  Histological disease (e.g., UCEIS, MRS and Geb oes Index) along with Mayo score assessments 
will also be completed.
8. Sigmoidoscopy may be performed on a separate day within the Day 43 visit window allowance ( 3 days).  A separate visit to perform sigmoidoscopy is only allowed to 
accommodate scheduling.  Thi s separate visit should be done before the full Day 43 visit where PK, clinical laboratory tests and all other required Day 4 3 procedures are 
performed.  Participants must not take their study medication at home in the morning before the sigmoidoscopy proc edure and also the morning before the full Day 43 visit, if 
being done on a separate day. Dispensing of study medication must be done at the 2ndvisit (if separate visits are performed).
9. Biopsy only required at Early Withdrawal visit if after at least 14 days of treatment and prior to Day 43 or if after Day 57 and prior to Day 85.
10. Participants must take study medication three times a day approximately 8 hours apart. Exact time of dosing to be recorded in diary cards. On Day 43 and 85, participants must 
nottake their study medication at home in the morning. Participant will complete specified pre -dose assessments and then will be administered their morning dose of medication 
at site on Day 43.  On Day 85, participants are no longer receiving study medicatio n.
11. In Part A, participants will be randomised 2:1 to GSK298 2772 60 mg or placebo three times daily for 42 days.  At the Day 43 visit, all participants who have completed Part A, will 
move in to Part B open label treatment with GSK2982772 60 mg three times daily for 42 days.
12. If urine pregnancy test is positive, a confirmatory serum pregnancy test must be performed.
13. Urinalysis not required on Days 29, 57 and 71.
14. Participants can provide a faecal sample at any time during the screening window and up to 48 hour s prior to any visit where FCP is being collected.  Please see laboratory 
manual for full details on sample handling and procedure.
15. Blood samples for exploratory biomarkers and Target engagement.  See laboratory manual for full details on sample collection , handling and shipment.
16. PK blood samples for GSK2982772 will be taken pre -dose on Day 43. Post- dose serial PK samples will be taken on Days 1 and Day 43 at the following time points: 1, 2, 4, and 6 
hours and trough on Day 85 or Early Withdrawal.
17. A PGx blo od sample is collected at the baseline visit (Day 1), after the participant has been randomized and provided informed consent for genetic research.  If the sample is not 
collected at the baseline visit, it can be collected at any time during the study afte r randomization.
18. Visit windows during the treatment period are relative to Day 1.
19. If a participant withdraws from the study, every effort will be made for the participant to complete an Early Withdrawal visi t prior to the Follow Up visit.
20. Follow -up visit s hould be completed 28 days ( 3 days) after the last dose of study medication. 
 
 2019N425893_00
CONFIDENTIA L
202152
4212.3. Appendix 3: A ssessment Windows
12.3.1. Definitions of A ssessment Windows for Analy ses
No Assessment Windows will be defined for Analy sis, and summaries and anal yses will 
be based on nom inal visits. 2019N425893_00
CONFIDENTIA L
202152
4312.4. Appendix 4: Study  Phases and Treatment Emergent 
Adverse Events
12.4.1. Study Phases
Treatment phases will be defined for Part A and Part B of the study . Therefore,
assessments and events will be classified according to the time of occurrence relative to 
study  treatment start date and the Day  43 visit.
Study Phase Definition
Pre-Treatment Date ≤ Study Treatment Start Date
On-Treatment Study Treatment Start Date < Date ≤ Study Treatment Stop Date
On-Treatment (Part A) Study Treatment Start Date < Date ≤ Day 43 Visit Date
On-Treatment (Part B) Day 43 Visit Date < Date ≤ Study Treatment Sto p Date
Post-Treatment Date > Study Treatment Stop Date 
12.4.1.1. Study  Phases for Concomitant Medication
Study Phase Definition
Prior If medication end date is not missing and is before 28 days prior to screening visit
Concomitant Any medication that is not a prior
Post- Treatment Any medication that is started >= Study Treatment Stop Date +1
NOTES: 
 Please refer to Appendix 7 : Reporting Standards for Missing Data for handling of missing and partial dates for 
concomitant medication. Use t he rules in this table if concomitant medication date is completely missing.
12.4.2. Treatment Emergent Flag for A dverse Events
Treatment State Definition
AE = Pre -TreatmentIf AE onset date is before treatment start date:
= AE Onset Date < Study Treatment Star t Date
AE = On -Treatment If AE onset date is on or after treatment start date and on or before treatment stop date:
= Study Treatment Start Date ≤ AE Start Date ≤ Study Treatment Stop Date +1
AE = Post- Treatment If AE onset date i s after the treatment stop date:
= AE Start Date > Study Treatment Stop Date +1
AE Onset Time 
Since 1stDose 
(Days)If Treatment Start Date ˃AE Onset Date: 
= AE Onset Date -Treatment Start Date
If Treatment Start Date ≤ AE Onset Date: 
= AE Onset Date - Treatment Start Date +1
Missing otherwise.
AE Duration (Days) AE Resolution Date –AE Onset Date + 1
AE = Drug -related If relationship is marked ‘YES’ on Inform/CRF OR value is missing .
NOTES: 
 If the study treatment stop date is missing, then the AE will be considered to be On -Treatment. 2019N425893_00
CONFIDENTIA L
202152
4412.5. Appendix 5: Data Display  Standards & Handling 
Conventions
12.5.1. Reporting Process
Software
The currently supported versions of SAS so ftware will be used.
Reporting Area for Interim Analysis 
HARP Server UK1SALX00175
HARP Area arenv \ arprod \gsk2982772 \mid202152 \interim1 
QC Spreadsheet arenv \ arwork \gsk2982772 \mid202152 \interim1 \documents
Reporting Area for Final Rep orting
HARP Server UK1SALX00175
HARP Area arenv \ arprod \gsk2982772 \mid202152 \final
QC Spreadsheet arenv \ arwork \gsk2982772 \mid202152 \final \documents
Analysis Datasets 
Analysis datasets will be created per Integrated Data Standards Lib rary (IDSL) GSK A&R dataset 
standards.
Generation of RTF Files
RTF files will be generated for all tables at the time of the SAC.
12.5.2. Reporting Standards
General
The current GSK Integrated Data Standards Library (IDSL) will be applied for reporting, unles s 
otherwise stated ( IDSL Standards Location: 
https://spope.gsk.com/sites/IDSLLibrary/SitePages/Home.aspx :
4.03 to 4.23: General Principles
5.01 to 5.08: Principles Related to Data Listings
6.01 to 6.11: Principles Related to Summary Tables
7.01 to 7.13: Principles Related to Graphics 
Participant level listings will not be provided in the main body of the GSK Clinical Study Report. All 
participant level listings will be located in the modular appendices as ICH or non -ICH listings.
Formats
GSK IDSL Statist ical Principles (5.03 & 6.06.3) for decimal places (DP’s) will be adopted for reporting of 
data based on the raw data collected, unless otherwise stated.
Numeric data will be reported at the precision collected on the eCRF.
The reported precision from non eCRF sources will follow the IDSL statistical principles but may be 
adjusted to a clinically interpretable number of DP’s. 
Planned and Actual Time
Reporting for tables, figures and formal statistical analyses:
Planned time relative to dosing will be use d in figures, summaries, statistical analyses and 
calculation of any derived parameters, unless otherwise stated.
The impact of any major deviation from the planned assessment times and/or scheduled visit days 
on the analyses and interpretation of the resu lts will be assessed as appropriate. 2019N425893_00
CONFIDENTIA L
202152
45Reporting for Data Listings: 
Planned and actual time relative to study drug dosing will be shown in listings (Refer to IDSL 
Statistical Principle 5.05.1).
Unscheduled or unplanned readings will be presented within the participant ’s listings. 
Unscheduled Visits
For all safety data:
Unscheduled visits will not be included in summary tables.
Unscheduled visits will not be included in figures.
All unscheduled visits will be included in listings.
For efficacy data:
Early withdrawal visit will be included in all summary tables, figures and listings
Early withdrawal visit will be assigned to closest planned study assessment following withdrawal i.e. 
for data collected from biopsies at the Day 43 visit or Day 85 visit
Descri ptive Summary Statistics
Continuous Data N, n, mean, median, SD, SE, min, max
Categorical Data N, n, frequency, %
Graphical Displays
Refer to IDSL Statistical Principals 7.01 to 7.13.
Placebo in graphs to be shown in Black and GSK2982772 in Green
12.5.3. Reporting Standards for Pharmacokinetic
Pharmacokinetic Concentration Data
Descriptive Summary 
Statistics, Graphical 
Displays and ListingsRefer to IDSL PK Display Standards.
Refer to IDSL Statistical Principle 6.06.1.
Note: Concentration values will be imputed as per GUI_51487 for descriptive 
summary statistics/analysis and summarized graphical displays only. 
NONMEM/PK/PD 
FilePK/PD file (CSV format) for the PK/PD analysis by Clinical Pharmacology 
Modelling and Simulation function mayl be created according to the data 
specification detailed in Appendix 12 : NONMEM datafile Specification. 2019N425893_00
CONFIDENTIA L
202152
4612.6. Appendix 6: Derived and Transformed Data
12.6.1. General
Multiple Measurements at One Analysis Time Point
Mean of the measurements will be c alculated and used in any derivation of summary statistics but if 
listed, all data will be presented.
Participant s having both High and Low values for Normal Ranges at any post -baseline visit for safety 
parameters will be counted in both the High and Low c ategories of “Any visit post -baseline” row of 
related summary tables. This will also be applicable to relevant Potential Clinical Importance (PCI) 
summary tables.
Study Day
Calculated as the number of days from First Dose Date:
Ref Date = Missing              → Study Day = Missing 
Ref Date < First Dose Date → Study Day = Ref Date – First Dose Date
Ref Data ≥ First Dose Date → Study Day = Ref Date – (First Dose Date ) + 1    
12.6.2. Study Population
Demographics
Date of Birth 
Only the year of birth will be ca ptured, and therefore the date of birth is then derived as follows:
Year of birth = YYYY → Date of birth = 30th June YYYY
Age
Calculated as the integer part of (date of screening   –date of birth)
       Age = integer part (date of study day 1   –30thJune YYYY)
Birth date will be presented in listings as ‘YYYY’.
Body Mass Index (BMI)
Calculated as Weight (kg) / [Height (m)2]
Race category 
White: ‘White: Arabic/North African Heritage’ and ‘White: White/Caucasian/European Heritage’, or both 
of these , but no other category checked .
African descent: ‘African American/African Heritage’, and no other category checked .
Asian: ‘Asian –Central/South Asian Heritage’, ‘Asian – East Asian Heritage’, ‘Asian –Japanese 
Heritage’, and ‘Asian –South East Asian Heritage’, or any combination of these, but no other category 
checked .
Other: Any combination that has not been categorized above (‘mixed race’).
Treatment Compliance
Participant compliance will be based on the number of expected tablets to be taken and t he number 
actually taken and will depend on whether a participant was taking investigational product (two tablets) 
twice a day or three times a day. 
Treatment compliance will be calculated based on the formula:  
Treatment Compliance = (Total tablets take n/total tablets expected to be taken) *100
Total tablets taken = (Total number of Tablets Dispensed -Total Tablets Returned) 
Total Tablets expected to be taken is duration of exposure*4 (see derivation below) for BID 
participant s and *6 for TID participant s. 2019N425893_00
CONFIDENTIA L
202152
47Demographics
Note compliance will only be calculated for participant s who took at least one dose (i.e. number of 
tablets taken is >=1 ).
Extent of Exposure
Number of days of exposure to study drug will be calculated based on the formula:  
Duration of Exposure in D ays = Treatment Stop Date –(Treatment Start Date) + 1
Participant s who were randomized but did not report a treatment start date will be categorised as 
having zero days of exposure. 
The cumulative dose will be based on the formula: Cumulative Dose = Total Tablets taken*60 .
Concomitant Medications
The following information will be added to the baseline characteristics table: 
Concomitant Medications for UC : Participant s will be categorized into one of 4 groups based on 
their ongoing prior concomitant med ications : 
Glucocorticoids only,
Immunosuppressants only,  
Glucocorticoids and immunosuppressants and 
No glucocorticoids or immunosuppressants .
Prednisone dose (or equivalent) : Summary statistics will be presented .
Glucocorticoids, Immunosuppressants and Prednisone will be identified by review of GSK drug terms by 
clinical and medical team.
12.6.3. Safety
ECG Parameters
RR Interval
IF RR interval (msec) is not provided directly, then RR can be derived as:
[1]IfQTcB is machine read & QTcF is not provided, then:
[2]If QTcF is machine read and QTcB is not provided, then: 
If ECGs are manually read, the RR value preceding the measurement QT interval should be a 
collected value then do not derive.
Corrected QT Intervals
When not entered directly in the eCRF, corre cted QT intervals by Bazett’s (QTcB) and 
Fridericia’s (QTcF) formulas will be calculated, in msec, depending on the availability of other 
measurements.
IF RR interval (msec) is provided then missing QTcB and/or QTcF will be derived as:  2019N425893_00
CONFIDENTIA L
202152
48Laboratory Pa rameters
If a laboratory value which is expected to have a numeric value for summary purposes, has a 
non-detectable level reported in the database, where the numeric value is missing, but typically 
a character value starting with ‘<x’ or ‘>x’ (or indicate d as less than x or greater than x in the 
comment field) is present, the number of decimal places in the observed values will be used to 
determine how much to add or subtract in order to impute the corresponding numeric value. 
oExample 1: 2 Significant Dig its = ‘< x ‘becomes x –0.01
oExample 2: 1 Significant Digit   = ‘> x’ becomes x + 0.1
oExample 3: 0 Significant Digits = ‘< x’ becomes x – 1    
12.6.4. Efficacy
Clinical Efficacy
Mayo
The Mayo is a 12 -point scoring system used to assess UC disease activity ba sed 4 subscores: , 
 and  The following table 
describes how each subscore is composed: 
Subscore Score
The following endpoints for the Mayo score are to be considered using the following algorithms : 
Mayo Endoscopy Remission:   Participant s with a score or or  on the
subscore.
Total Mayo Score: the total score of all 4 domain subscores -
and 
Partial Mayo Score: the total score of the 3 domain subscores - and  2019N425893_00
CCI
CCI
C
C
I
C
C
I
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are 
protected by third party copyright laws and therefore have been excluded.
CCI
CONFIDENTIA L
202152
49Clinical Efficacy
3-domain Mayo Score: the total score of the 3 domain subscores: and 
Mayo Clinical Response: ≥3 points or ≥30% improvement from baseline in total Mayo score , along with 
a decrease in the subscore of ≥1 point. 
oi.e.,(< change from baseline in total mayo score <= OR% change from baseline in total 
mayo score <= )AND change from baseline in subscore <= .
3-domain Mayo Clinical Response: ≥2points or ≥30% improvement from baseline in partial Mayo score, 
along with a decrease in the subscore of ≥1 point or a  subscore of or . 
oi.e., ( < change from baseline in partial mayo score <= OR % change from baseline in 
partial mayo score <= )AND (change from baseline in subscore <= OR 
 subscore of or ). 
Mayo Clinical Remission: Total Mayo score of 2 points or lower, with no individual subscore ex ceeding 1 
point.
oi.e., <= total mayo score <= AND  subscore =  or AND
subscore =  or  AND  subscore = or  AND  
subscore = or . 
3-domain Mayo Clinical Remission: At least one point decrease in  subscore from 
Baseline to achieve a  subscore of  or  and subscore =  and
 subscore of or .
oi.e. (  subscore  or  AND change from baseline in subscore <= 
)AND subscore of  AND subscore =  or 
.
Clinical Efficacy 
UCEIS
The UCEIS is used as an additional tool to assess disease activity based o n endoscopic , 
and . The following table describes how the UCEIS is scored:
Descriptor (score most
severe lesions)Likert scale anchor points Definition 2019N425893_00
CCI
CCI
CCI
CCI
CCI
C
CI
C
C
I
CCI
CC
I
C
C
I
CCI
C
CI
C
C
I
CC
I
CCI
CCI
C
CI
C
CI
C
CI
C
CI
C
C
I
C
C
I
CCI
C
CI
C
C
I
C
CI
C
C
I
CCI
C
CI
C
C
I
C
C
I
CCI
CCI
C
CI
C
C
I
C
CI
C
C
I
C
C
I
C
C
I
C
C
I
C
C
I
C
CI
C
C
I
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
C
C
I
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected 
by third party copyright laws and therefore have been excluded.
CCI
CCI
CCI
CONFIDENTIA L
202152
50Clinical Efficacy
The following endpoint for the UCEIS is to be considered at each visit: 
UCEIS Total Score:   Sum of all likert scale anchor points scores. 
UCEIS Remission: Participant s with a score or 0 or 1 on the UCEIS Total Score.
Geboes
The Geboes Index is divided in 6 grades: architectural changes [grade 0], chronic inflammatory infiltrate [grade 1], 
lamina propria neutrophils and eosinophils [grade 2], neutrophils in epithelium [grade 3], crypt destruction [grade 
4] and erosions or ulcerations [grade 5], and each grade of the score is divided in 4 or5 subcategories. 
Grade Subgrade
0 Structural (architectural change) 0.0 No abnormality
0.1 Mild abnormality
0.2 Mild or moderate diffuse or multi focal 
abnormalities
0.3 Severe diffuse or multifocal abnormalities
1 Chronic inflammatory infiltrate 1.0 No increase
1.1 Mild but unequivocal increase
1.2 Moderate increase
1.3 Marked increase
2 Lamina propria eosinophils and 
neutrophils (to be graded separately)2.0 No increase
2.1 Mild but unequivocal increase
2.2 Moderate increase
2.3 Marked increase
3 Neutrophils in epithelium 3.0 None
3.1 <5% crypts involved
3.2 =<50% crypts involved
3.3 >=50% crypts involved
4 Crypt destruction 4.0 None
4.1 Probable –local excess of neutrophils in part 
of crypt 2019N425893_00
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected 
by third party copyright laws and therefore have been excluded.
CONFIDENTIA L
202152
51Clinical Efficacy
4.2 Probable –marked attenuation
4.3 Unequivocal crypt destruction
5 Erosion or ulcerative 5.0 No erosion, ulceration, or granulation tissue
5.1 Recovering epith elium plus adjacent 
inflammation
5.2 Probable erosion –focally stripped
5.3 Unequivocal erosion
5.4 Ulcer or granulation tissue
The following endpoint for the Geboes is to be considered at each relevant visit: 
Geboes Index Total Score:   Sum of the all the subgrades (i.e. Structural (architectural change) = 0.2 is a 
score of 2, Chronic inflammatory infiltrate = 1.1 is scored as a 1 etc.).

Robarts Histology Index (RHI)
The RHI will be provided by Robarts as an additional tool to measure histologic disease activity. 
The RHI Score is a continuous score, ranging from 0 -33 with h igher scores indicating more severe disease.
For the frequency table of RHI Score the following cut -points will be used: 
Remission: Score <= 6, 
Low: Scores >6-<12, 
Moderate/Severe Score: > = 12
Modified Riley Scale
The Modified Riley Scale (MRS) is a 4 -point scale (none, mild, moderate and severe) which scores histologic 
activity based on localization and quantification of neutrophils in the mucosa. A single mod ified riley scale score is 
collected at each relevant visit.  
Activity Histological Characteristics
None 0 Normal biopsy or inactive colitis
Mild 1 Lamina propria neutrophils only = Scattered 
individual neutrophils
2 Lamina propria neutrophils o nly = Patchy 
collections of neutrophils
3 Lamina propria neutrophils only = Diffuse 
neutrophils infiltrate
Moderate 4 Cryptitis/crypt abscesses = <25%  crypts involved
5 Cryptitis/crypt abscesses = 25% -74% crypts 
involved
6 Cryptitis/crypt absce sses = >=75% crypts 
involved
Severe 7 Erosion or ulceration = Present 2019N425893_00
CONFIDENTIA L
202152
52Clinical Efficacy
Faecal Calprotectin (FCP)
FCP, a protein biomarker, is measured from the faecal samples. The raw FCP data is highly variable and 
therefore data should be log -transformed before a change from baseline is calculated. 
For the frequency table of FCP categories the following cut -points will be used: 
<250, 
>=250 and 
>=1000.
C-Reactive Protein (CRP)
CRP will be provided as a clinical chemistry parameter in the Clinical Laborato ry dataset.
Inflammatory Bowel Disease Questionnaire (IBDQ)
The IBDQ is a 32 -item Inflammatory Bowel Disease -specific health related quality of life instrument evaluating 
general activities of daily living, intestinal function, social performance, pers onal interactions, and emotional 
status. Each item is presented on seven -point scale with higher representing better functioning. 
The IBDQ items are grouped into four domains with a total score for each being calculated as follows:
Bowel symptoms (10 it ems): Sum items 1, 5, 9, 13, 17, 20, 22, 24, 26, 29
Systemic Symptoms (5 items): Sum items 2, 6, 10, 14, 18.
Emotional Function (12 items): Sum items 3, 7, 11, 15, 19, 21, 23, 25, 27, 30, 31, 32
Social Function (5 items): Sum items 4, 8, 12, 16 and 28
The IBDQ Total Score is calculated as follows:
IBDQ Total Score:   Sum of all 32 -items. 
Subject Symptom Diary Cards
Participants will be given a diary card at each visit. The number of stools, stool frequency score and rectal 
Bleeding Score will be trans cribed into the eCRF for the 5 days prior to the following visits: Screening, Day 15, 
Day 29, Day 43, Day 85 and EW. 
The stool frequency score is on a 4 -point scale as follows: 
0 =Normal
1 = 1- 2 stools/day more than normal
2 = 3- 4 stools/day more than normal
3 =>=4 stools/day more than normal 
The rectal bleeding score is on a 4 -point scale as follows: 
0 =Noblood seen
1 =Streaks of blood with stool less than half the time
2 =Obvious blood with stool most of the time  2019N425893_00
CONFIDENTIA L
202152
53Clinical Efficacy
3 = B lood alone passed.
The average score and maximum score be considered for both stool frequency and rectal bleeding over the 5 
days prior to at each visit: 
Average Score: [ Sum of scores over 5 prior days] / [number of prior days with a score available] 
Maximum Score: Maximum ( i.e. highest) score collected over 5 prior days. 
The average score will be considered for number of stools over the 5 days prior to at each visit: 
Average Score: [ Sum of number of stools over 5 prior days] / [number of prior days with a stool data 
available] 
12.6.5. Biomarker
TEAR
Target Engagement
Ratio = free / total
Target Engagement = 100 –(ratio post/ratio baseline ) * 100))
BIOMARK dataset:
BICAT = TRIPK1 (total) or FRIPK1 (free) and BITESTCD = CONC  2019N425893_00
CONFIDENTIA L
202152
5412.7. Appendix 7: Reporting Standards for Missing Data
12.7.1. Premature Withdrawals
Element Reporting Detail
General Participant study completion was defined as one who has completed all phases of the 
study including the follow -up visit. 
Withdrawn participants may be replaced in the study at the discretion of the 
investigator.
All available data from participants who were withdrawn from the study will be listed 
and all available planned data will be included in summary tables and figures, unless 
otherwise specified. 
12.7.2. Handling of Missing Data
Element Reporting Deta il
General Missing data occurs when any requested data is not provided, leading to blank fields on 
the collection instrument:
These data will be indicated by the use of a “blank” in participant listing displays. 
Unless all data for a specific visit are mi ssing in which case the data is excluded 
from the table. 
Answers such as “Not applicable” and “Not evaluable” are not considered to be 
missing data and should be displayed as such.
Outliers Any participants excluded from the summaries and/or statistical analyses will be 
documented along with the reason for exclusion in the clinical study report.
12.7.2.1. Handling of Missing and Partial Dates
Element Reporting Detail
General Partial dates will be displayed as captured in participant listing displays.
Adverse 
EventsThe eCRF allows for the possibility of partial dates (i.e., only month and year) to be 
recorded for AE start and end dates; that is, the day of the month may be missing. In 
such a case, the following conventions will be applied for calculating the time to onset 
and the duration of the event:
Missing Start Day: First of the month will be used unless this is before the start 
date of study treatment; in this case the study treatment start date will be used and 
hence the event is considered On -treatment as per Appendix 4 : Study Phases and 
Treatment Emergent Adverse Events.
Missing Stop Day: Last day of the month will be used, unless this is after the stop 
date of study treatment; in this case the study treatment stop dat e will be used.
Completely missing start or end dates will remain missing, with no imputation applied. 
Consequently, time to onset and duration of such events will be missing.
Concomitant 
Medications/Partial dates for any concomitant medications recorded in the CRF will be imputed 
using the following convention:
If the partial date is a start date, a '01' will be used for the day and 'Jan' will be used for 
the month
If the partial date is a stop date, a '28/29/30/31' will be used for the day (dependent 
on the month and year) and 'Dec' will be used for the month.
The recorded partial date will be displayed in listings. 2019N425893_00
CONFIDENTIA L
202152
5512.8. Appendix 8: Values of Potential Clinical Importance
12.8.1. Laboratory  Values
Haematology
Laboratory Parameter Units Category Clinical Concern R ange
Low Flag (< x) High Flag (>x)
Hematocrit Ratio of 
1Male 0.54
Female 0.54
∆from BL ↓0.075
Hemoglobin g/LMale 180
Female 180
∆from BL ↓25
Lymphocytes x109/ L 0.8
Neutrophil Count x109/ L 1.5
Platelet Count x109/ L 100 550
While Blood Cell Count (WBC) x109/ L 3 20
Clinical Chemistry
Laboratory Parameter Units Category Clinical Concern Range
Low Flag (< x) High Flag (>x)
Albumin g/L 30
Calcium mmol/L 2 2.75
Creatinine µmol/L ∆from BL ↑ 44.2
Glucose mmol/L 3 9
Magnesium mmol/L 0.5 1.23
Phosphorus mmol/L 0.8 1.6
Potassium mmol/L 3 5.5
Sodium mmol/L 130 150
Total CO2 mmol/L 18 32
Liver Function
Test Analyte Units Category Clinical Concern Range
ALT/SGPT U/L High 2x ULN
AST/SGOT U/L High 2x ULN
AlkPhos U/L High 2x ULN
T Bilirubin µmol/L High 1.5xULN
T. Bilirubin + ALTµmol/L
High1.5xULN T. Bilirubin
+
U/L 2x ULN ALT 2019N425893_00
CONFIDENTIA L
202152
5612.8.2. ECG
ECG Parameter Units Clinical Concern Range
Lower Upper
Absolute
Absolute QTc Inte rval msec> 450 ≤ 479 
≥ 480 ≤ 499
≥ 500 
Absolute PR Interval msec < 110 > 220 
Absolute QRS Interval msec < 75 > 110
Change from Baseline
Increase from Baseline QTcmsec > 30 <60
msec ≥60 
12.8.3. Vital Signs
Vital Sign Parameter
(Absolute)Units Clinical Concern Range
Lower Upper
Systolic Blood Pressure mmHg < 85 > 160
Diastolic Blood Pressure mmHg < 45 > 100
Heart Rate bpm < 40 > 110
Vital Sign Parameter
(Change from Baseline)Units Clinical Concern Range
Decrease Increase
Lower Upper Lower Upper
Systolic Blood Pressure mmHg ≥ 20 ≥ 40 ≥ 20 ≥ 40
Diastolic Blood Pressure mmHg ≥ 10 ≥ 20 ≥ 10 ≥ 20
Heart Rate bpm ≥ 15 ≥ 30 ≥ 15 ≥ 30 2019N425893_00
CONFIDENTIA L
202152
5712.9. Appendix 9: Abbreviations & Trade Marks
12.9.1. Abbrev iations
Abbreviation Description
AE Adverse Event
A&R Analysis and Reporting 
AIC Akaike's Infor mation Criteria
BID Twice a day
CI Confidence Interval
CRF Case Report Form
CRP C-Reactive Protein
CSR Clinical Study Report
C-SSRS Columbia Suicide Severity Rating Scale
CTR Clinical Trial Register
CV b / CV w Coefficient of Variation (Between) / Co efficient of Variation (Within)
DB Double -Blind
DBF Database Freeze
DBR Database Release
DOB Date of Birth
DP Decimal Places
DRC Data Review Committee
ECG Electrocardiogram
eCRF Electronic Case Record Form
EMA European Medicines Agency
FCP Faecal Calprotectin
FDA Food and Drug Administration
FDAAA Food and Drug Administration Clinical Results Disclosure Requirements
GEE Generalised Estimating Equations
GSK GlaxoSmithKline
IA Interim Analysis
IBDQ Inflammatory Bowel Disease Questionnaire
ICH International Conference on Harmonization
IDSL Integrated Data Standards Library
IMMS International Modules Management System
IP Investigational Product
IRTS Interactive Response Technology System
ITT Intent -To-Treat
Kg Kilogram
mmol Millimole
MMR M Mixed Model Repeated Measures
MRS Modified Riley Sc ale
NR Normal Range
OL Open -Label
PCI Potential Clinical Importance 
PD Pharmacodynamic
PDMP Protocol Deviation Management Plan
PK Pharmacokinetic
PopPK Population PK
PP Per Protocol 2019N425893_00
CONFIDENTIA L
202152
58Abbreviation Description
PP Per Pro tocol
PSRAE Possible Suicidality -Related Adverse Event
PT Preferred Term
QC Quality Control
QTcB Bazett’s QT Interval Corrected for Heart Rate
QTcF Frederica’s QT Interval Corrected for Heart Rate
RAMOS Randomization & Medication Ordering System 
RAP Reporting & Analysis Plan
RHI Robarts Histology Index
SAC Statistical Analysis Complete
SAE Serious Adverse Event
SE Standard Error
SOC System Organ Class
SOP Standard Operation Procedure
SRT Safety Review Team
TA Therapeutic Area
TEAR1 Target Engagement Assay RIP1
TFL Tables, Figures & Listings 
TID Three times a day
UC Ulcerative Colitis
UCEIS Ulcerative Colitis Endoscopic Index of Severity
ULN Upper Limit of Normal
12.9.2. Trademarks
Trademarks of the GlaxoSmithKline 
Group of CompaniesTradema rks not owned by the 
GlaxoSmithKline Group of Companies
RandALL MedDRA
NONMEM
SAS 2019N425893_00
CONFIDENTIA L
202152
5912.10. Appendix 10: List of Data Display s
12.10.1. Data Display  Numbering
The following numbering will be applied for RAP generated display s:
Section Tables Figures
Study Populat ion 1.1 to 1. 16 NA
Efficacy 2.1 to 2. 41 2.1 to 2. 44
Safety 3.1 to 3. 56 3.1 to 3. 7
Pharmacokinetic 4.1 4.1 to 4. 28
Pharmacodynamic and / or Biomarker 6.1 to 6. 11 6.1 to 6. 19
Section Listings
ICH Listings 1 to 42
Other Listings 43 to 83
12.10.2. Mock Exam ple Shell Referencing
Non IDSL  specifications will be referenced as indicated and if required example mock-up 
display s provided in Appendix 11: Example Mock Shells for Data Display s
Section Figure Table Listing
Study Population POP_F n POP_Tn POP_Ln
Efficacy EFF_Fn EFF_Tn EFF_Ln
Safety SAFE_Fn SAFE_Tn SAFE_Ln
Pharmacokinetic PK_Fn PK_Tn PK_Ln
Pharmacodynamic and / or Biomarker PD_Fn PD_Tn PD_Ln
NOTES: 
 Non-Standard displays are indicated in the ‘IDSL / Example Shell’ or ‘Programmi ng Notes’ column as ‘[Non -
Standard] + Reference.’
12.10.3. Deliverables
Delivery [Priority] [1] Description
IA SAC [X] Interim Analysis Statistical Analysis Complete
SAC [X] Final Statistical Analysis Complete
SAC2 [X] Post- Final Statistical Analysis Complete
NOTES: 
1. Indicates priority (i.e. order) in which displays will be generated for the reporting effort 2019N425893_00
CON FIDENTIA L
202152
6012.10.4. Study Population Tables
Study Population Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Subject Dispositio n
1.1. Safety ES1Summary of Subject Disposition for the Subject Conclusion 
Record by Randomised Treatment ICH E3, FDAAA, EudraCT
Footnote: Add footnote : Note: 
“Subjects” is used to refer to 
“Participants” in all data displays to 
reflect GSK Display Standar dsIA SAC[1],
SAC [1]
1.2. Safety SD1Summary of Treatment Status and Reasons for Discontinuation 
of Study Treatment by Randomised TreatmentICH E3IA SAC [1], 
SAC [1]
1.3. All Subjects ES6Summary of Screening Status and Reasons for Screen Failure
by Randomise d TreatmentJournal RequirementsIASAC [1], 
SAC [1]
1.4. All Subjects NS1Summary of Number of Subjects by Country and Site ID by 
Randomised TreatmentEudraCT/ Clinical OperationsIA SAC [1], 
SAC [1]
Protocol Deviation
1.5. Safety DV1Summary of Important Prot ocol Deviations by Randomised 
TreatmentICH E3IA SAC [1], 
SAC [1]
Population Analysed
1.6. Safety SP1 Summary of Study Populations by Randomised Treatment IDSLIA SAC [1], 
SAC [1]
1.7. SafetySP2 / 
SP2ASummary of Exclusions from the PP and PP + Completer s
PopulationIDSL IA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
61Study Population Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Demographic and Baseline Characteristics
1.8. Safety DM1 Summary of Demographic Characteristics by Randomised 
TreatmentICH E3, FDAAA, EudraCT
If height and weight are collected 
only at baseline, then display in this 
demographic summary. Otherwise 
display height and weight with the 
vital signs data. IASAC [1], 
SAC [1]
1.9. All Subjects DM11 Summary of Age Ranges by Randomised Treatment EudraCTIA SAC [1], 
SAC [1]
1.10. Safety DM5Summary of Race and Racial Combinations by Random ised 
TreatmentICH E3, FDA, FDAAA, EudraCTIA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
62Study Population Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
1.11. Safety DM1Summary of Ulcerative Colitis Baseline Characteristics by 
Randomised TreatmentTo include:
Baseline Mucosal Appearance at 
Endoscopy Mayo Subscore, Baseline 
Total Mayo Score,
Baseline Partial Mayo Score Baseline 
3-domain Mayo Score, Baseline UCEIS 
Total Score, Baseline Modified Riley 
ScaleScore,
Baseline FCP, 
Baseline FCP category, 
Baseline Concomitant Medications for 
UC (Glucocorticoids only, 
Immunosuppressants only, 
Glucocortic oids and 
Immunosuppressants, No 
Glucocorticoids or 
Immunosuppressants, 
Baseline Prednisone dose,
Family History of Premature Coronary 
Artery Disease and History of Tobacco 
Use.
Include the footnote:
Note: Glucocorticoids and 
Immunosuppressants were identified by 
review of all ingredients by clinical and 
medical team.IA SAC[1],
SAC [1]
Prior/Current Medical Conditions and Concomitant Medications
1.12. Safety MH4Summary of Current/Past Medical Conditions by Randomised 
TreatmentICH E3 
Separate summaries for Current & 
Past conditions, if collected.IA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
63Study Population Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
1.13. Safety MH1 Summary of Current/Past Cardiovascular Risk Factors by 
Randomised TreatmentICH E3
Separate summaries for Current & 
Past, if collectedIASAC [1], 
SAC [1]
1.14. Safety CM1 Summary of P rior Medications by Randomised TreatmentICH E3 IA SAC [1], 
SAC [1]
1.15. Safety CM1Summary of Concomitant Medications by Randomised 
TreatmentICH E3IA SAC [1], 
SAC [1]
Exposure and Treatment Compliance
1.16. SafetyEX1 / 
EX5Summary of Exposure to Study Tre atment by Randomised 
TreatmentICH E3IA SAC [1], 
SAC [1]
12.10.5. Safety  Tables
Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
Adverse Events (AEs)
3.1. Safety AE5ASummary of All Adverse Events by Maximum Int ensity by 
System Organ Class and Preferred Term (Part A only) by 
Randomised TreatmentICH E3
Include total column across all 
intensitiesIASAC [1], 
SAC [1]
3.2. Safety AE5ASummary of All Adverse Events by Maximum Intensity by 
System Organ Class and Preferre d Term (Parts A, B and 
Follow -up)by Randomised TreatmentICH E3
Include total column across all 
intensitiesIASAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
64Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.3. Safety AE5ASummary of All Adverse Events by Maximum Intensity by 
System Organ Class and Preferred Term (Parts A, B and 
Follow- up)by Period TreatmentICH E3
Include total column across all 
intensitiesIA SAC[1], 
SAC [1]
3.4. Safety AE1Summary of All Adverse Events by System Organ Class and 
Preferred Term (Part A only) by Randomised TreatmentIA SAC[1],
SAC [1]
3.5. Safety AE1Summary of All Adverse Events by System Organ Class and 
Preferred Term (Parts A, B and Follow -up) by Randomised 
TreatmentIA SAC[1],
SAC [1]
3.6. Safety AE1Summary of All Adverse Events by System Organ Class and 
Preferred Term (Parts A, B and Follow -up) by Pe riod TreatmentIA SAC[1],
SAC [1]
3.7. Safety AE3Summary of Common (>=10%) Adverse Events by Overall 
Frequency (Part A only) by Randomised TreatmentICH E3
Common defined as >= 10% within 
either randomised treatment groupIASAC [1], 
SAC [1]
3.8. Safety AE3Summary of Common (>=10%) Adverse Events by Overall 
Frequency (Parts A, B and Follow -up) by Randomised 
TreatmentICH E3
Common defined as >= 10% within 
either randomised treatment groupIA SAC[1], 
SAC [1]
3.9. Safety AE3Summary of Common (>=10%) Adverse Ev ents by Overall 
Frequency (Parts A, B and Follow -up) by Period TreatmentICH E3
Common defined as >= 10% within 
either randomised treatment groupIA SAC[1], 
SAC [1]
3.10. Safety AE5ASummary of All Drug -Related Adverse Events by Maximum 
Intensity and System Organ Class and Preferred Term (Part A 
only) by Randomised TreatmentICH E3
Include total column across all 
intensitiesIA SAC [ 1], 
SAC [1]
3.11. Safety AE5ASummary of All Drug -Related Adverse Events by Maximum 
Intensity and System Organ Class and Preferred Term (Parts A, 
B and Follow -up) by Randomised TreatmentICH E3
Include total column across all 
intensitiesIASAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
65Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.12. Safety AE5ASummary of All Drug -Related Adverse Events by Maximum 
Intensity and System Organ Class and Preferred Term (Parts A,
B and Follow -up) by Period TreatmentICH E3
Include total column across all 
intensitiesIASAC [1], 
SAC [1]
3.13. Safety AE15Summary of Common (>=10%) Non -serious Adverse Events by 
System Organ Class and Preferred Term (Number of Subjects 
and Occurrences) (P art A only) by Randomised TreatmentFDAAA, EudraCT IA SAC [ 1], 
SAC [1]
3.14. Safety AE15Summary of Common (>=10%) Non -serious Adverse Events by 
System Organ Class and Preferred Term (Number of Subjects 
and Occurrences) (Parts A, B and Follow -up) by Randomis ed 
TreatmentFDAAA, EudraCT IASAC [1], 
SAC [1]
3.15. Safety AE15Summary of Common (>=10%) Non -serious Adverse Events by 
System Organ Class and Preferred Term (Number of Subjects 
and Occurrences) (Parts A, B and Follow -up) by Period 
TreatmentFDAAA, EudraCT IASAC [1], 
SAC [1]
3.16. Safety AE3Summary of Common (>=10%) Drug -Related Adverse Events 
by Overall Frequency (Part A only) by Randomised TreatmentICH E3 IASAC [1], 
SAC [1]
3.17. Safety AE3Summary of Common (>=10%) Drug -Related Adverse Events 
by Overall Frequency (Parts A, B and Follow -up) by 
Randomised TreatmentICH E3 IA SAC [ 1], 
SAC [1]
3.18. Safety AE3Summary of Common (>=10%) Drug -Related Adverse Events 
by Overall Frequency (Parts A, B and Follow -up) by Period 
TreatmentICH E3 IA SAC [ 1], 
SAC [1]
Serious and Other Significant Adverse Events
3.19. Safety AE16Summary of Serious Adverse Events by System Organ Class 
and Preferred Term (Number of Subjects and Occurrences) 
(Part A only) by Randomised TreatmentFDAAA, EudraCT IASAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
66Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.20. Safety AE16Summary of Serious Adverse Events by System Organ Class 
and Preferred Term (Number of Subjects and Occurrences) 
(Parts A, B and Follow -up) by Randomised TreatmentFDAAA, EudraCT IA SAC [ 1],
SAC [1]
3.21. Safety AE16Summary of Serious Adverse Events by Syste m Organ Class 
and Preferred Term (Number of Subjects and Occurrences) 
(Parts A, B and Follow -up) by Period TreatmentFDAAA, EudraCT IA SAC [1], 
SAC [1]
3.22. Safety AE1 Summary of Adverse Events Leading to Permanent 
Discontinuation of Study Treatment or With drawal from Study 
(Part A only) by Randomised TreatmentIDSL IASAC [1], 
SAC [1]
3.23. Safety AE1 Summary of Adverse Events Leading to Permanent 
Discontinuation of Study Treatment or Withdrawal from Study
(Parts A, B and Follow -up) by Randomised TreatmentIDSL IASAC [1], 
SAC [1]
3.24. Safety AE1 Summary of Adverse Events Leading to Permanent 
Discontinuation of Study Treatment or Withdrawal from Study
(Parts A, B and Follow -up) by Period TreatmentIDSL IASAC [1], 
SAC [1]
Laboratory: Chemistry 
3.25. Safety LB1Summary of Chemistry Changes from Baseline (Parts A, B and 
Follow -up) by Randomised TreatmentICH E3 IASAC [1], 
SAC [1]
3.26. Safety LB1Summary of Chemistry Changes from Period Baseline (Parts A, 
B and Follow -up) by Period TreatmentICH E3 IA SAC [ 1], 
SAC [ 1]
3.27. Safety LB1Summary of Lipids Percentage Changes from Baseline (Parts A, 
B and Follow -up) by Randomised TreatmentLipids parameters = LDL 
Cholesterol, HDL Cholesterol, Total 
Cholesterol, Triglycerides and 
Cholesterol/HDL ratioIA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
67Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.28. Safety LB1Summary of Lipids Percentage Changes from Period Baseline 
(Parts A, B and Follow -up) by Period TreatmentLipids parameters = LDL 
Cholesterol, HDL Cholesterol, Total 
Cholesterol Triglycerides and 
Cholesterol/HDL ratioIA SAC[1],
SAC [1]
3.29. Safet y LB17Summary of Worst Case Chemistry Results by PCI Criteria 
Post- Baseline Relative to Baseline (Parts A, B and Follow -up) by 
Randomised TreatmentICH E3 (i.e. treatment emergent) IA SAC [1], 
SAC [1]
3.30. Safety LB17Summary of Worst Case Chemistry Results by PCI Criteria 
Post- Baseline Relative to Period Baseline (Parts A, B and 
Follow -up) by Period TreatmentICH E3 (i.e. treatment emergent) IA SAC [1], 
SAC [1]
3.31. Safety LB17Summary of Worst Case Lipids Results by NR Criteria Post -
Baseline Relative to Base line (Parts A, B and Follow -up) by 
Randomised TreatmentLipids parameters = LDL 
Cholesterol, HDL Cholesterol, Total 
CholesterolTriglycerides and 
Cholesterol/HDL ratioIASAC [1], 
SAC [1]
3.32. Safety LB17Summary of Worst Case Lipids Results by NR Criteria Pos t-
Baseline Relative to Period Baseline (Parts A, B and Follow -up) 
by Period TreatmentLipids parameters = LDL 
Cholesterol, HDL Cholesterol, Total 
Cholesterol, Triglycerides and 
Cholesterol/HDL ratioIASAC [1], 
SAC [1]
Laboratory: Hematology
3.33. Safety LB1Summary of Hematology Changes from Baseline (Parts A, B 
and Follow -up) by Randomised TreatmentICH E3 IA SAC [1], 
SAC [1]
3.34. Safety LB1Summary of Hematology Changes from Period Baseline (Parts 
A, B and Follow -up) by Period TreatmentICH E3 IA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
68Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.35. Safety LB17Summary of Worst Case Hematology Results by PCI Criteria 
Post- Baseline Relative to Baseline (Parts A, B and Follow -up) by 
Randomised TreatmentICH E3 IA SAC [1], 
SAC [1]
3.36. Safety LB17Summary of Worst Case Hematology Results by PCI Cr iteria 
Post- Baseline Relative to Period Baseline (Parts A, B and 
Follow -up) by Period TreatmentICH E3 IA SAC [1], 
SAC [1]
Laboratory: Urinalysis
3.37. Safety LB1Summary of Urine Concentration Changes from Baseline (Parts 
A, B and Follow -up) by Randomised Treatment ICH E3 IA SAC [1], 
SAC [1]
3.38. Safety LB1Summary of Urine Concentration Changes from Period Baseline 
(Parts A, B and Follow -up) by Period TreatmentICH E3 IA SAC [1], 
SAC [1]
3.39. Safety UR1Summary of Worst Case Urinalysis Results (Discrete or 
Character Values) Post -Baseline Relative to Baseline (Parts A, 
B and Follow -up) by Randomised TreatmentICH E3 IA SAC [1], 
SAC [1]
3.40. Safety UR1Summary of Worst Case Urinalysis Results (Discrete or 
Character Values) Post -Baseline Relative to Period Baseline 
(Parts A, B and Follow -up) by Period TreatmentICH E3 IA SAC [1], 
SAC [1]
Laboratory: Hepatobiliary (Liver)
3.41. Safety LIVER1Summary of Liver Monitoring/Stopping Event Reporting (Parts A, 
B and Follow -up) by Randomised TreatmentIDSLIA SAC [1], 
SAC [1]
3.42. Safety LIVER1Summary of Liver Monitoring/Stopping Event Reporting (Parts A, 
B and Follow -up) by Period TreatmentIDSLIA SAC [1], 
SAC [1]
3.43. Safety LIVER10Summary of Hepatobiliary Laboratory Abnormalities (Parts A, B 
and Follow -up) by Randomised Trea tmentIDSL IASAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
69Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.44. Safety LIVER10Summary of Hepatobiliary Laboratory Abnormalities (Parts A, B 
and Follow -up) by Period TreatmentIDSL IASAC [1], 
SAC [1]
ECGs
3.45. Safety EG1Summary of ECG Findings (Parts A, B and Follow -up) by 
Randomised TreatmentIDSL IA SAC [1], 
SAC [1]
3.46. Safety EG1Summary of ECG Findings (Parts A, B and Follow -up) by Period 
TreatmentIDSL IASAC [1], 
SAC [1]
3.47. Safety EG10Summary of Maximum QTc Values Post -Baseline Relative to 
Baseline by Category (Parts A, B and Follow -up) by 
Randomised TreatmentIDSLIASAC [1], 
SAC [1]
3.48. Safety EG10Summary of Maximum QTc Values Post -Baseline Relative to 
Screening by Category (Parts A, B and Follow -up) by 
Randomised TreatmentChange relative to a verage of 
screening triplicates SAC[1]
3.49. Safety EG10Summary of Maximum QTc Values Post -Baseline Relative to 
Period Baseline by Category (Parts A, B and Follow -up) by 
Period TreatmentIDSLIA SAC [1], 
SAC [1]
3.50. Safety EG2Summary of Change from Baseline in ECG Values (Parts A, B 
and F ollow -up) by Randomised TreatmentIDSL IA SAC [1], 
SAC [1]
3.51. Safety EG2Summary of Change from Screening in ECG Values (Parts A, B 
and Follow -up) by Randomised TreatmentChange relative to average of 
screening triplicatesSAC [1]
3.52. Safety EG2Summary of C hange from Period Baseline in ECG Values (Parts 
A, B and Follow -up) by Period TreatmentIDSL IA SAC [1], 
SAC [1]
3.53. Safety EG11Summary of Maximum Increase in QTc Values Post -Baseline 
Relative to Baseline by Category (Parts A, B and Follow -up) by 
Randomised TreatmentIDSLIA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
70Safety : Tables
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.54. Safety EG11Summary of Maximum Increase in QTc Values Post -Baseline 
Relative to Screening by Category (Parts A, B and Follow -up) by 
Randomised TreatmentChange relative to average of 
screening triplicates SAC [1]
3.55. Safety EG11Summary of Maximum Increase in QTc Values Post -Baseline 
Relative to Period Baseline by Category (Parts A, B and Follow -
up) by Period TreatmentIDSLIASAC [1], 
SAC [1]
Vital Signs
3.56. Safety VS1Summary of Change from Baseline in Vital Signs (Parts A, B 
and Follow -up) by Randomised TreatmentICH E3 IASAC [1], 
SAC [1]
3.57. Safety VS1Summary of Change from Period Baseline in Vital Signs (Parts 
A, B and Follow -up) by Period TreatmentICH E3 IASAC [1], 
SAC [1]
3.58. Safety VS7Summary of Worst Case V ital Signs Results by PCI Criteria 
Post- Baseline Relative to Baseline (Parts A, B and Follow -up) by 
Randomised TreatmentIDSLIA SAC [1], 
SAC [1]
3.59. Safety VS7Summary of Worst Case Vital Signs Results by PCI Criteria 
Post- Baseline Relative to Period Baseline (Parts A, B and 
Follow -up) by Period TreatmentIDSLIASAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
7112.10.6. Safety  Figures
Safety : Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Adverse Events
3.1. Safety AE10Plot of Common (>=10%) Adverse Events and Relative Risk
(Part A only) by Randomised TreatmentIDSLIASAC [1], 
SAC [1]
3.2. Safety AE10Plot of Common (>=10%) Adverse Events and Relative Risk 
(Parts A, B and Follow -up)by Randomised TreatmentIDSLIASAC [1], 
SAC [1]
3.3. Safety AE10Plot of Common (>=10%) Adverse Events and Relative Risk 
(Parts A, B and Follow -up)by Period TreatmentIDSLIASAC [1], 
SAC [1]
Laboratory
3.4. Safety LIVER14Scatter Plot of Maximum Versus Baseline for ALT (Parts A, B 
and Follow -up)by Randomised TreatmentIDSL IASAC [1], 
SAC [1]
3.5. Safety LIVER14Scatter Plot of Maximum Versus Period Baseline for ALT (Parts 
A, B and Follow -up)by Period TreatmentIDSL IA SAC [1], 
SAC [1]
3.6. Safety LIVER9Scatter Plot of Maximum ALT Versus Maximum Total Bilirubin 
ALT (Parts A, B and Follow -up)by Randomised TreatmentIDSL IA SAC [1], 
SAC [1]
3.7. Safety LIVER9Scatter Plot of Maximum ALT Versus Maximum Total Bilirubin 
(Parts A, B and Follow -up)by Period TreatmentIDSL IA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
7212.10.7. Efficacy  Tables
Efficacy: Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Mayo – Endoscop yRespons e
2.1. Safety EFF_T1Summary Statistics for Actual and Change from Baseline in
Mucosal A ppearance at Endoscopy Mayo Subscore (Parts A
and B) by Randomised Tre atmentIA SAC [1], 
SAC [1]
2.2. Safety EFF_T2 bFrequency Table of Mucosal Appearance at Endoscopy Mayo 
Subscore (Parts A and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
2.3. Safety EFF_T3GEE Point Estimate and 95% CI for Subjects Achieving Mayo 
Endoscopy Remission (Parts A and B) by Randomised 
TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
2.4. PP EFF_T1Summary Statistics for Actual and Change from Baseline in 
Mucosal Ap pearance at Endoscopy Mayo Subscore (Parts A 
and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
2.5. PP EFF_T2bFrequency Table of Mucosal Appearance at Endoscopy Mayo 
Subscore (Parts A and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
2.6. PP EFF_T3GEE Poi nt Estimate and 95% CI for Subjects Achieving Mayo 
Endoscopy Remission (Parts A and B) by Randomised 
TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
2.7.PP + 
CompletersEFF_T1Summary Statistics for Actual and Change from Baseline in 
Mucosal Appearance at Endoscopy Mayo Subscore (Parts A 
and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
2.8.PP + 
CompletersEFF_T2bFrequency Table of Mucosal Appearance at Endoscopy Mayo 
Subscore (Parts A and B) by Randomised TreatmentIA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
73Efficacy: Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
2.9.PP + 
CompletersEFF_T3GEE Point Estimate and 95% CI for Subjects Achieving Mayo 
Endoscopy Remission (Parts A and B) by Randomised 
TreatmentGEE modelling will only be 
performed if at le ast 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
Mayo – Clinical Response and Remission
2.10. Safety EFF_T2aFrequency Table of Subjects Achieving Mayo Clinical Response, 
3-domain Clinical Response, Mayo Clinical Remission and 3-
Domain Mayo Clinical Remission (Parts A and B) by 
Randomised TreatmentIA SAC [1], 
SAC [1]
2.11. Safety EFF_T3GEE Point Estimate and 95% CI for Subjects Achieving Mayo 
Clinical Response, 3-domain Mayo Clinical Response, Mayo 
Clinical Remission and 3 -domain Mayo Clinical Remission 
(Parts A and B) by Randomised TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
2.12. PP EFF_T2aFrequency Table of Subjects Achieving Mayo Clinical Response, 
3-domain Clinical Response, Mayo Clinical Remission and 3 -
Domain Mayo Clinical Remission (Parts A and B) by 
Randomised TreatmentIA SAC [1], 
SAC [1]
2.13. PP EFF_T3GEE Point Estimate and 95% CI for Subjects Achieving Mayo 
Clinical Response, 3 -domai n Mayo Clinical Response, Mayo 
Clinical Remission and 3 -domain Mayo Clinical Remission 
(Parts A and B) by Randomised TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
2.14.PP + 
CompletersEFF_T2aFrequency Table of Subjects Achieving Mayo Clinical Response, 
3-domain Clinical Response, Mayo Clinical Remission and 3 -
Domain Mayo Clinical Remission (Parts A and B) by 
Randomised TreatmentIA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
74Efficacy: Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
2.15.PP + 
CompletersEFF_T3GEE Point Estimate and 95% CI for Subjects Achieving Mayo 
Clinical Response, 3 -domain Mayo Clinical Response, Mayo 
Clinical Remission and 3 -domain Mayo Clinical Remission 
(Parts A and B) by Randomised TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
Mayo – Symptomatic Clinical Remission  
2.16. Safety EFF_T1Summary Statistics for Actual and Change from Baseline in 
Total, Partial and 3 -domain Mayo Scores (Parts A and B) by 
Randomised TreatmentIA SAC [1], 
SAC [1]
2.17. Safety EFF_T4Adjusted Mean (95% CI) of the Change from Baseline in Total, 
Partial and 3 -domain Mayo Scores (Parts A and B) by 
Randomised TreatmentIA SAC [1], 
SAC [1]
2.18. PP EFF_T1Summary Statistics for Actua l and Change from Baseline in 
Total, Partial and 3 -domain Mayo Scores (Parts A and B) by 
Randomised TreatmentIA SAC [1], 
SAC [1]
2.19. PP EFF_T4Adjusted Mean (95% CI) of the Change from Baseline in Total, 
Partial and 3 -domain Mayo Scores (Parts A and B) by 
Randomised TreatmentIA SAC [1], 
SAC [1]
2.20.PP + 
CompletersEFF_T1Summary Statistics for Actual and Change from Baseline in 
Total, Partial and 3 -domain Mayo Scores (Parts A and B) by 
Randomised TreatmentIA SAC [1], 
SAC [1]
2.21.PP + 
CompletersEFF_T4Adjus ted Mean (95% CI) of the Change from Baseline in Total, 
Partial and 3 -domain Mayo Scores (Parts A and B) by 
Randomised TreatmentIA SAC [1], 
SAC [1]
UCEIS –Mucosal Healing 
2.22. Safety EFF_T1Summary Statistics for Actual and Change from Baseline in 
UCEIS Total Score (Parts A and B) by Randomised TreatmentIA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
75Efficacy: Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
2.23. Safety EFF_T4Adjusted Mean (95% CI) of the Change from Baseline in UCEIS 
Total Score (Parts A and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
UCEIS –Remission 
2.24. Safety EFF_T2aFrequency Table of Subjects Achieving UCEIS Remission (Parts 
A and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
2.25. Safety EFF_T3GEE Point Estimate and 95% CI for Subjects Achieving UCEIS 
Remission (Parts A and B) by Randomised TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
Biomarkers of Disease Activity
2.26. Safety EFF_T1Summary Statistics for Actual and Change from Baseline in CRP 
(Parts A and B) by Randomised Tre atmentIA SAC [1], 
SAC [1]
2.27. Safety EFF_T4Adjusted Mean (95% CI) of the Change from Baseline in CRP 
(Parts A and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
2.28. Safety EFF_T2bFrequency Table of FCP Categories (Parts A and B) by 
Randomised TreatmentIA SAC [1], 
SAC [1]
2.29. Safety EFF_T1Summary Statistics for Actual and Log -Transformed Change 
from Baseline in FCP (Parts A and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
2.30. Safety EFF_T4Adjusted Mean (95% CI) of the Log -transformed Change from 
Baseline in FCP (Parts A and B) by Randomised TreatmentInclude related estimated adjusted 
geometric means and treatment 
differencesIA SAC [1], 
SAC [1]
Histologic Disease Activity
2.31. Safety EFF_T2bFrequency Table of Modified Riley Scale Categories (Parts A 
and B ) by Randomised TreatmentIA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
76Efficacy: Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
2.32. Safety EFF_T1Summary Statistics for Actual and Change from Baseline in 
Modified Riley Scale Score (Parts A and B) by Randomised 
TreatmentIA SAC [1], 
SAC [1]
2.33. Safety EFF_T4Adjusted Mean (95% CI) of the C hange from Baseline in 
Modified Riley Scale Score (Parts A and B) by Randomised 
TreatmentIA SAC [1], 
SAC [1]
2.34. Safety EFF_T2 bFrequency Table of RHI Categories (Parts A and B) by 
Randomised TreatmentIA SAC [1], 
SAC [1]
2.35. Safety EFF_T1Summary Statistic s for Actual and Change from Baseline in RHI 
Score (Parts A and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
2.36. Safety EFF_T4Adjusted Mean (95% CI) of the Change from Baseline in RHI 
Score (Parts A and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
2.37. Safety EFF_T1Summary Statistics for Actual and Change from Baseline in 
Geboes Index Total Score (Parts A and B) by Randomised 
TreatmentIA SAC [1], 
SAC [1]
2.38. Safety EFF_T4Adjusted Mean (95% CI) of the Change from Baseline in 
Geboes Index Total Score (Parts A and B) by Randomised 
TreatmentIA SAC [1], 
SAC [1]
Quality of Life
2.39. Safety EFF_T1Summary Statistics for Actual and Change from Baseline in 
IBDQ Domain Scores and Total Score (Parts A and B) by 
Randomised Treatment SAC [1]
2.40. Safety EFF_T4Adjusted Mean (95% CI) of the Change from Baseline in IBDQ 
Total Score (Parts A and B) by Randomised TreatmentSAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
77Efficacy: Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Subject Symptom Diary Cards
2.41. Safety EFF_T1Summary Statistics of Average and Maximum Stool Frequency 
Score over 5 days from Subject Symptom D iary (Parts A and B) 
by Randomised TreatmentInclude Average and Maximum 
Stool Frequency Score, Average 
and Maximum Rectal Bleeding 
Score and Average Number of 
Stools.SAC [1]
12.10.8. Efficacy  Figures
Efficacy: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Mayo
2.1. Safety EFF_F1Individual Subject Profiles for Subjects Achieving Mayo 
Endoscopy Remission, Total Mayo Score, Partial Mayo Score, 
3-domain Mayo Score , Mayo Clinical Response, 3 -domain Mayo 
Clinical Response, Mayo Clinical Remission and 3 -domain 
Clinical Remission over Time (Parts A and B) by Randomised 
TreatmentSeparate pages for each endpoint. IA SAC [1], 
SAC [1]
2.2. Safety EFF_F4Proportion of Subjects Achieving Mayo Endoscopy Remission 
and over Time (Parts A and B) by Randomised TreatmentLine graph with randomised 
treatment on the same plotIA SAC [1], 
SAC [1]
2.3. Safety EFF_F3Odds Ratio and 95% CI for Proportion of Subjects Achieving 
Mayo Endoscopy Remission (Parts A and B) by Randomised 
Treatment GEE mod elling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
78Efficacy: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
2.4. Safety EFF_F4Proportion of Subjects Mayo Clinical Response, 3 -domain Mayo 
Clinical Response, Mayo Clinical Remission and 3 -domain 
Clinical Remission over Time (Parts A and B) by Randomised 
Treatment  Separate pages for each endpoint.
Line graph with randomised 
treatment on the same plot.IA SAC [1], 
SAC [1]
2.5. Safety EFF_F3Odds Ratio and 95% CI for Achieving Mayo Clinical Response, 
3-domain Mayo Clinical Response, Mayo Clinical Remission and 
3-domain Clinical Remission over Time (Parts A and B) by 
Randomised Treatment  Separate pages for each endpoint. 
GEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
2.6. Safety EFF_F2Mean ( SE) Total, Partial and 3 -domain Mayo Scores over Time 
(Parts A and B) by Randomised Treatment  Separate pages for each endpoint. IA SAC [1], 
SAC [1]
2.7. Safety EFF_F3Point Estimates and 95% C I of Change from Baseline in Total, 
Partial and 3 -domain Mayo Scores over Time (Parts A and B) by 
Randomised Treatment  Separate pages for each endpoint.
Grey dashed line at y=0. IA SAC [1], 
SAC [1]
2.8. PP EFF_F1Individual Subject Profiles for Subjects A chieving Mayo 
Endoscopy Remission, Total Mayo Score, Partial Mayo Score, 
3-domain Mayo Score , Mayo Clinical Response, 3 -domain Mayo 
Clinical Response, Mayo Clinical Remission and 3 -domain 
Clinical Remission over Time (Parts A and B) by Randomised 
TreatmentSeparate pages for each endpoint. IA SAC [1], 
SAC [1]
2.9. PP EFF_F4Proportion of Subjects Achieving Mayo Endoscopy Remission 
and over Time (Parts A and B) by Randomised TreatmentLine graph with randomised 
treatment on the same plotIA SAC [1], 
SAC [1]
2.10. PP EFF_F3Odds Ratio and 95% CI for Proportion of Subjects Achieving 
Mayo Endoscopy Remission (Parts A and B) by Randomised 
Treatment GEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
2.11. PP EFF_F4 Proportion of Subjects Mayo Clinical Response, 3 -domain Mayo Separate pages for each endpoint. IA SAC [1],  
 
 2019N425893_00
CON FIDENTIA L
202152
79Efficacy: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Clinical Response, Mayo Clinical Remission and 3 -domain 
Clinical Remission over Time (Parts A and B) by Randomised 
Treatment  Line graph with r andomised 
treatment on the same plot.SAC [1]
2.12. PP EFF_F3Odds Ratio and 95% CI for Achieving Mayo Clinical Response, 
3-domain Mayo Clinical Response, Mayo Clinical Remission and 
3-domain Clinical Remission over Time (Parts A and B) by 
Randomised Treatment  Separate pages for each endpoint. 
GEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
2.13. PP EFF_F2Mean ( SE) Total, Partial and 3 -domain Mayo Scores over Time 
(Parts A and B) by Randomised Treatment  Separate pages for each endpoint. IA SAC [1], 
SAC [1]
2.14. PP EFF_F3Point Estimates and 95% CI of Change from Baseline in Total, 
Partial and 3 -domain Mayo Scores over Time (Parts A and B) by 
Randomised Treatment  Separate pages for each endpoint.
Grey dashed line at y=0. IA SAC [1], 
SAC [1]
2.15.PP + 
CompletersEFF_F1Individual Subject Profiles for Subjects Achieving Mayo 
Endoscopy Remission, Total Mayo Score, Partial Mayo Score, 
3-domain Mayo Score , Mayo Clinical Response, Mayo Clinical 
Remission and 3 -domain Clinical Remission over Time (Parts A 
and B) by Randomised TreatmentSeparate pages for each endpoint. IA SAC [1], 
SAC [1]
2.16.PP + 
CompletersEFF_F4Proportion of Subjects Achieving Mayo Endoscopy Remission 
and over Ti me (Parts A and B) by Randomised TreatmentLine graph with randomised 
treatment on the same plotIA SAC [1], 
SAC [1]
2.17.PP + 
CompletersEFF_F3Odds Ratio and 95% CI for Proportion of Subjects Achieving 
Mayo Endoscopy Remission (Parts A and B) by Randomised 
Treatment GEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
2.18.PP + 
CompletersEFF_F4Proportion of Subjects Mayo Clinical Response, 3 -domain Mayo 
Clinical Response, Mayo Clinical Remission and 3 -domain 
Clinical Remission over Time (Parts A and B) by Randomised Separate pages for each endpoint.
Line graph with randomised 
treatment on the same plot.IA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
80Efficacy: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Treatment  
2.19.PP + 
CompletersEFF_F3Odds Ratio and 95% CI for Ac hieving Mayo Clinical Response, 
3-domain Mayo Clinical Response, Mayo Clinical Remission and 
3-domain Clinical Remission over Time (Parts A and B) by 
Randomised Treatment  Separate pages for each endpoint. 
GEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1]
2.20.PP + 
CompletersEFF_F2Mean ( SE) Total, Partial and 3 -domain Mayo Scores over Time 
(Parts A and B) by Randomised Treatment  Separate pages for each endpoint. IA SAC [1], 
SAC [1]
2.21.PP + 
CompletersEFF_F3Point Estimates and 95% CI of Change from Baseline in Total, 
Partial and 3 -domain Mayo Scores over Time (Parts A and B) by 
Randomised Treatment  Separate pages for each endpoint.
Grey dashed line at y=0. IA SAC [1], 
SAC [1]
UCEIS
2.22. Safety EFF_F1Individual Subject Profiles for UCEIS Total Score over Time
(Parts A and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
2.23. Safety EFF_F2Mean ( SE) UCEIS Total Score over Time (Parts A and B) by 
Randomised Treatment  IA SAC [1], 
SAC [1]
2.24. Safety EFF_F3Point Estimates and 95% CI of Change from Baseline in UCEIS 
Total Score over Time (Parts A and B) by Randomised 
Treatment  Grey dashed line at y=0. IA SAC [1], 
SAC [1]
2.25. Safety EFF_F4Proportion of Subjects Achieving UCEIS Clinica l Remission over 
Time (Parts A and B) by Randomised Treatment  Line graph with randomised 
treatment on the same plot.IA SAC [1], 
SAC [1]
2.26. Safety EFF_F3Odds Ratio and 95% CI for Achieving UCEIS Clinical Remission 
over Time (Parts A and B) by Randomised Treatment  GEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one treatment 
group.IA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
81Efficacy: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Biomarkers of Disease Activity 
2.27. Safety EFF_F1Individual Subject Profiles for CRP and FCP over Time (Parts A 
and B) by Randomised TreatmentSeparate pages for each endpoint. IA SAC [1], 
SAC [1]
2.28. Safety EFF_F2Mean ( SE) CRP over Time (Parts A and B) by Randomised 
Treatment  IA SAC [1], 
SAC [1]
2.29. Safety EFF_F3Point Estimates and 95% CI of Change from Baseline in CR P 
over Time (Parts A and B) by Randomised Treatment  Grey dashed line at y=0. IA SAC [1], 
SAC [1]
2.30. Safety EFF_F2Mean ( SE) FCP over Time (Parts A and B) by Randomised 
Treatment  IA SAC [1], 
SAC [1]
2.31. Safety EFF_F3Point Estimates and 95% CI of Change from Baseline in log -
transformed FCP over Time (Parts A and B) by Randomised 
Treatment  Grey dashed line at y=0. IA SAC [1], 
SAC [1]
Histologic Disease Activity
2.32. Safety EFF_F1Individual Subject Profiles for Modified Riley Scale Score over 
Time (Parts A and B) by Randomised TreatmentSeparate pages for each endpoint. IA SAC [1], 
SAC [1]
2.33. Safety EFF_F2Mean ( SE) Modified Riley Scale Score over Time (Parts A and 
B) by Randomised Treatment  Separate pages for each endpoint.IA SAC [1], 
SAC [1]
2.34. Safety EFF_F3Point Estimates and 95% CI of Change from Baseline in 
Modified Riley Scale Score over Time (Parts A and B) by 
Randomised Treatment  Separate pages for each endpoint.
Grey dashed line at y=0. IA SAC [1], 
SAC [1]
2.35. Safety EFF_F1Individual Subj ect Profiles for RHI Total Score over Time (Parts 
A and B) by Randomised TreatmentIA SAC [1], 
SAC [1]
2.36. Safety EFF_F2Mean ( SE) RHITotal Score over Time (Parts A and B) by 
Randomised Treatment  IA SAC [1], 
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
82Efficacy: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
2.37. Safety EFF_F3Point Estimates and 95% CI of Change from Baseline in RHI
Total Score over Time (Parts A and B) by Randomised 
Treatment  Grey dashed line at y=0. IA SAC [1], 
SAC [1]
2.38. Safety EFF_F1Individual Subject Profiles for Geboes Index Total Score over 
Time (Parts A and B) by Rando mised TreatmentIA SAC [1], 
SAC [1]
2.39. Safety EFF_F2Mean ( SE) Geboes Index Total Score over Time (Parts A and 
B) by Randomised Treatment  IA SAC [1], 
SAC [1]
2.40. Safety EFF_F3Point Estimates and 95% CI of Change from Baseline in Geboes 
Index Total Score over Time (Parts A and B) by Randomised 
Treatment  Grey dashed line at y=0. IA SAC [1], 
SAC [1]
Quality of Life
2.41. Safety EFF_F1Individual Subject Profiles for IBDQ Total Score over Time 
(Parts A and B) by Randomised TreatmentSeparate pages for each endpoint. SAC [1]
2.42. Safety EFF_F2Mean ( SE) IBDQ Total Score over Time (Parts A and B) by 
Randomised Treatment  SAC [1]
2.43. Safety EFF_F3Point Estimates and 95% CI of Change from Baseline in IBDQ 
Total Score over Time (Parts A and B) by Randomised 
Treatment  Grey dashed line at y=0. SAC [1]
Responder Across Efficacy Endpoints
2.44. Safety EFF_F4Individual Subject Profile Plot of Efficacy Endpoints over Time 
(Parts A and B) by Randomised TreatmentSeparate pages for each Subject 
9 panel plot with a pane l for: 
(order change following IA )
Top Row: Total Mayo Score, Partial 
Mayo Score, 3 -domain Mayo ScoreIA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
83Efficacy: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Middle Row: Mayo Endoscopy 
Remission, Mayo Rectal Bleed,
UCEIS Total Score,
Bottom Row: Geboes Index Total 
Score , FCP, CRP
12.10.9. Pharmac okinetic Tables
Pharmacokinetic : Tables
No. PopulationIDSL /
Example ShellTitle Programming NotesDeliverable 
[Priority]
PK concentration data 
4.1. PK PK01 Summary of GSK2982772 Concentration -Time Data (ng/mL)Separate summaries for blood and 
biopsy tissue s amples. 
Pre-dose: Day 43, Post -dose: Day 1 
and 43 at 1, 2, 4 and 6 hours.IA SAC [1]
SAC [1]
Summary of GSK2982772 Predicted Trough Concentrations
(ng/mL)Predicted trough Day 43 
 
 2019N425893_00
CON FIDENTIA L
202152
8412.10.10. Pharmacokinetic Figures
Pharmacokinetic : Figures
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
Individual PK Concentration
4.1.
Mean/Median Concentration
4.2. PK PKCF2Mean ( SE) Plot: GSK2982772 Concentrations versus Time
(Linear) on Day 1 and Day 43 (60 mg TID only)IA SAC [1 ]
SAC [1]
4.3.
Trough Concentration 
4.4. PKGSK2982772 Observed pre -dose Concentration Data vs Day (60 
TID only)Separate pages for plasma
Spaghetti Plot of individual trough 
concentrations vs day.IA SAC [1]
SAC [1]
4.5. PK GSK2982772 Observed Pre-Dose Concentration Data vs DayPlot of individual trough 
concentrations vs day overlaid 
with box and whisker plot.IA SAC [1]
SAC [1]
4.6. PK PD_F1Scatter Plot GSK2982772 Observed Pre-Dose Plasma
Concentration Versus Biopsy Pre-Dose Tissue ConcentrationX axis –Plasma
Y axis –BiopsyIA SAC [1]
SAC [1]
PK/PD
4.7. PK PD_F1Scatter Plot of Individual GSK2982772 Pre-Dose Concentration s
Versus Individual Pre-Dose % Target Engagement Separate pages sample type 
(Plasma/Biopsy)
X axis –PK concentration,
Y axis –TEIA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
85Pharmacokinetic : Figures
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
4.8. PK PD_F1Box Plots of GSK2982772 Day 43 Predicted Trough 
Concentration for participants not a chieving Mayo Endoscopy 
Remission and for participants a chieving Mayo Endoscopy 
Remission Separate pages sample type 
(predicted trough /Biopsy)
X axis –Non Mayo Endoscopy 
Remission / Mayo Endoscopy 
Remission
Y axis –PK ConcIA SAC [1]
SAC [1]
4.9. PK PD_F1Scatter Plot of Individual GSK2982772 Predicted Trough 
Concentration Versus Change from Baseline in Total Mayo 
Score Separate pages sample typ e 
(Blood/Biopsy)
X axis –PK concentration,
Y axis –Efficacy Parameter IA SAC [1]
SAC [1]
4.10. PK PD_F1Scatter Plot of Individual GSK2982772 Predicted Trough 
Concentration Versus Change from Baseline in Partial Mayo 
Score Separate pages sample type 
(Blood /Biopsy)
X axis –PK concentration,
Y axis –Efficacy Parameter IA SAC [1]
SAC [1]
4.11. PK PD_F1Scatter Plot of Individual GSK2982772 Predicted Trough 
Concentration Versus Change from Baseline in 3 -domain Mayo 
Score Separate pages sample type 
(Blood/Biopsy )
X axis –PK concentration,
Y axis –Efficacy Parameter IA SAC [1]
SAC [1]
4.12. PK PD_F1Scatter Plot of Individual GSK2982772 Predicted Trough 
Concentration Versus Change from Baseline in UCEIS Total 
Score Separate pages sample type 
(Blood/Biopsy)
X axis –PK concentration,
Y axis –Efficacy Parameter IA SAC [1]
SAC [1]
4.13. PK PD_F1Scatter Plot of Individual GSK2982772 Predicted Trough 
Concentration Versus Change from Baseline in Modified Riley 
Scale Score Separate pages sample type 
(Blood/Biopsy)
X axis –PK concentration,
Y axis –Efficacy Parameter IA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
86Pharmacokinetic : Figures
No. PopulationIDSL / Example 
ShellTitle Programming NotesDeliverable 
[Priority]
4.14. PK PD_F1Scatter Plot of Individual GSK2982772 Predicted Trough 
Concentration Versus Change from Baseline in RHI  Separate pages sample type 
(Blood/Biopsy)
X axis –PK concentration,
Y axis –Efficacy Parameter IA SAC [1]
SAC [1]
4.15. PK PD_F1Scatter Plot of Individual GSK2982772 Predicted Trough 
Concentration Versus Change from Baseline in Geboes Index 
Total Score Separate pages sample type 
(Blood/Biopsy)
X axis –PK concentration,
Y axis –Efficacy Parameter IA SAC [1]
SAC [1]
4.16. PK PD_F1Scatter Plot of Individual GSK2982772 Predicted Trough 
Concentration Versus Change from Baseline in CRPSeparate pages sample type 
(Blood/Biopsy)
X axis –PK concentration,
Y axis –Efficacy ParameterIA SAC [1]
SAC [1]
4.17. PK PD_F1Scatter Plot of Individual GSK2982772 Predicted Trough 
Concentration Versus Change from Baseline in FCPSeparate pages sample type 
(Blood/Biopsy)
X axis –PK concentration,
Y axis –Efficacy Parameter IA SAC [1]
SAC [1]
4.18. PK PD_F1Scatter Plot of GSK2982772 Pre-Dose Concentration Versus 
Pre-Dose TEAR 1 % Target Engagement Separate pages sample type 
(Blood/Biopsy)
X axis –PK Trough 
concentration,
Y axis –TESAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
8712.10.11. Pharmacody namic and/or Biomarker Tables
Pharmacodynamic andBiomarker : Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Exploratory Biomarkers
6.1. Safety PD_T1Summary Statistics for Actual and Percentage Change from 
Baseline in Biopsy Tissue Inflammatory Biomarkers (Parts A and 
B) One page for each cell 
type/measure by visit/time and 
treatmentSAC [1]
6.2. Safety PD_T2Adjusted Mean (95% CI) of Percentage Change from Baseline in 
Biopsy Tissue Inflammatory Biomarkers (Parts A and B) One page for each cell 
type/measur e by visit/time and 
treatment/dosing regimenSAC [1]
Pathway and Target E ngagement
6.3. Safety EFF_T1Summary Statistics forObserved TEAR1 %Target Engagement 
(Parts A and B) Separate summaries for sample 
type (Blood/Biopsy)
% Target Engagement by visit/t imeSAC [1]
6.4.Summary Statistics for Predicted  TEAR1 % Target Engagement 
based on predicted GSK2982772 trough concentrations (Parts A 
and B)
6.5. Safety PD_T 3Adjusted Mean (95% CI) of TEAR1 %  Target Engagement in 
Blood (Parts A and B) by Randomised Trea tmentSAC [1]
6.6. Safety PD_T3Adjusted Mean (95% CI) of TEA R1 %  Target Engagement in 
Biopsy Tissue (Parts A and B) by Randomised TreatmentSAC [1]
6.7. SafetyEFF_T1 Summary Statistics of Pathway Engagement (Parts A and B) by 
Randomised TreatmentSeparate su mmaries for sample 
type (Blood/Biopsy)SAC [1]
6.8. Safety PD_T3Adjusted Mean (95% CI) of Pathway Engagement in Blood 
(Parts A and B) by Randomised TreatmentSAC [1]
6.9. Safety PD_T3Adjusted Mean (95% CI) of Pathway Engagement in Biopsy 
Tissue (Parts A and B ) by Randomised TreatmentSAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
88Pharmacodynamic andBiomarker : Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
mRNA Expression 
6.10. Safety PD_T4Summary of mRNA Expression of Inflammatory Gene 
Transcripts (Parts A and B) by Randomised TreatmentSeparate summaries for sample 
type (Blood/Biopsy)
qPCR –micarray datasetSAC2 [1]
6.11. Safety PD_T5Frequency Table Summarising the Number of Probe Sets with 
Various Fold Change (Parts A and B) by Randomised TreatmentSeparate summaries for sample 
type (Blood/Biopsy).
Use cut -offs 1.5 and -1.5 initially.  
Change to - 1.25 and 1.5 if no one 
achieves the initial cut -offsSAC2 [1]
6.12. Safety PD_T6Summary of Adjusted Mean Fold Changes in mRNA Expression 
of Inflammatory Gene Transcripts (Parts A and B) by 
Randomised TreatmentSeparate summaries for sample 
type (Blood/Biopsy).
If Adj Mean FC lies betwe en -1 and 
1 then do not include on tableSAC2 [1]
6.13. SafetySummary of Analysis for Microaray mRNA Intensity Data in 
Blood  GSK to produce 
Only to be produced for significant 
probsets based on adjusted p -values.
If Adj Mean FC lies between -1 and 1 
then do not include on tableSAC2 [1]
6.14. SafetySummary of mRNA Percentage Inhibition of Inflammatory 
Gene Transcripts in Blood GSK to produce
Only to be produced for significant 
probsets based on adjusted p -values.SAC2 [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
89Pharmacodynamic andBiomarker : Tables
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
6.15. SafetySummary of Analysis for Microaray mRNA Percentage Inhibition 
Data in Blood  GSK to produce 
Only to be produced for significant 
probsets based on adjusted p -values.
If Adj Mean FC lies between -1 and 1 
then do not include on tableSAC2 [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
9012.10.12. Pharmacody namic and/or Biomarker Figures
Pharmacodynamic and or Biomark er: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Exploratory Biomarkers
6.1. Safety EFF_F1Individual Subject Profiles for Biopsy Tissue Inflammatory 
Biomarkers over Time (Parts A and B) by Randomised 
TreatmentSeparate pages for each endpoint. SAC [1]
6.2. Safety EFF_F3Point Estimates and 95% CI for Percentage Change from 
Baseline inBiopsy Tissue Inflammatory Biomarkers over Time 
(Parts A and B) by Randomised TreatmentSAC [1]
Pathway and Target Engagement
6.3. Safety EFF_F1Individual Subject Profiles for TEAR1 % Target Engagement 
(Parts A and B) by Randomised TreatmentSeparate pages sample type 
(Blood/Biopsy)
Panel plot, line colours by treatment 
group, subjid as cell hea derSAC [1]
6.4. Safety EFF_F3Point Estimates and (95% CI) TEAR1 %  Target Engagement in 
Blood (Parts A and B) by Randomised TreatmentSAC [1]
6.5. Safety EFF_F3Point Estimates and (95% CI) TEAR1 %  Target Engagement in 
Biopsy Tissue (Parts A and B) by Randomi sed TreatmentSAC [1]
6.6. Safety PD_F1Scatter Plot of TEAR 1 % Target Engagement in Blood Versus 
TEAR1 %  Target Engagement in Biopsy Tissue by Randomised 
Treatment SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
91Pharmacodynamic and or Biomark er: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
6.7. PK PD_F1Scatter Plot of TEAR 1 % Target Engagement 
Versus Proportion Achieving Mayo Endoscopy Remission 
Randomised TreatmentSeparate pages sample type 
(Blood/Biopsy)
X axis –PK concentration,
Y axis –Efficacy Parameter SAC2[1]
6.8. Safety PD_F1Scatter Plot of TEAR1 % Target Engagement Versus Change 
from Baseline in Total Mayo Sco reby Randomised TreatmentSeparate pages for each biomarker 
parameter and sample type (blood/ 
Biopsy)
X axis –Target Engagement,
Y axis –Efficacy Parameter 
Different markers for each 
randomised treatment groupSAC2[1]
6.9. Safety PD_F1Scatter Plot of TE AR1 % Target Engagement Versus Change 
from Baseline in Partial Mayo Score by Randomised TreatmentSeparate pages for each biomarker 
parameter and sample type (blood/ 
Biopsy)
X axis –Target Engagement,
Y axis –Efficacy Parameter 
Different markers for eac h 
randomised treatment groupSAC2[1]
6.10. Safety PD_F1Scatter Plot of TEAR1 % Target Engagement Versus Change 
from Baseline in 3-domain Mayo Score by Randomised 
TreatmentSeparate pages for each biomarker 
parameter and sample type (blood/ 
Biopsy)
X axis – Target Engagement,
Y axis –Efficacy Parameter 
Different markers for each 
randomised treatment groupSAC2[1] 
 
 2019N425893_00
CON FIDENTIA L
202152
92Pharmacodynamic and or Biomark er: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
6.11. Safety PD_F1Scatter Plot of TEAR1 % Target Engagement Versus Change 
from Baseline in UCEIS Total Score by Randomised TreatmentSeparate pages f or each biomarker 
parameter and sample type (blood/ 
Biopsy)
X axis –Target Engagement,
Y axis –Efficacy Parameter 
Different markers for each 
randomised treatment groupSAC2[1]
6.12. Safety PD_F1Scatter Plot of TEAR1 % Target Engagement Versus Change 
from Baseline in Modified Riley Scale Score by Randomised 
TreatmentSeparate pages for each biomarker 
parameter and sample type (blood/ 
Biopsy)
X axis –Target Engagement,
Y axis –Efficacy Parameter 
Different markers for each 
randomised treatment groupSAC2 [1]
6.13. Safety PD_F1Scatter Plot of TEAR1 % Target Engagement Versus Change 
from Baseline in RHI by Randomised TreatmentSeparate pages for each biomarker 
parameter and sample type 
(blood/Biopsy)
X axis –Target Engagement,
Y axis –Efficacy Parameter 
Different markers for each 
randomised treatment groupSAC2[1] 
 
 2019N425893_00
CON FIDENTIA L
202152
93Pharmacodynamic and or Biomark er: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
6.14. Safety PD_F1Scatter Plot of TEAR1 % Target Engagement Versus Change 
from Baseline in Geboes Index Total Score by Randomised 
TreatmentSeparate pages for each biomarker 
parameter and sample type 
(blood/Biopsy)
X axis –Target Engagement,
Y axis –Efficacy Parameter 
Different markers for each 
randomised treatment groupSAC2[1]
6.15. Safety PD_F1Scatter Plot of TEAR1 % Target Engagement Versus Change 
from Baseline in CRP by Randomised TreatmentSepara te pages for each biomarker 
parameter and sample type 
(blood/Biopsy)
X axis –Target Engagement,
Y axis –Efficacy Parameter 
Different markers for each 
randomised treatment groupSAC2[1]
6.16. Safety PD_F1Scatter Plot of TEAR1 % Target Engagement Versus Cha nge 
from Baseline in FCP by Randomised TreatmentSeparate pages for each biomarker 
parameter and sample type 
(blood/Biopsy)
X axis –Target Engagement,
Y axis –Efficacy Parameter 
Different markers for each 
randomised treatment groupSAC2[1]
mRNA Expres sion
6.17. Safety EFF_F1Individual Subject Profiles for mRNA Expression of Inflammatory 
Gene Transcripts (Parts A and B) by Randomised TreatmentSeparate pages for each gene and 
sample type (blood/Biopsy). SAC2 [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
94Pharmacodynamic and or Biomark er: Figures
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
6.18. Safety PD_F2Adjusted Mean Intensities f or mRNA Expression of Inflammatory 
Gene Transcripts (Parts A and B) by Randomised TreatmentSeparate pages for each gene and 
sample type (blood/biopsy). 
. SAC2 [1]
6.19. Safety PD_F3Adjusted Mean (95% CI) Fold Change in mRNA Expression of 
Inflammatory Gen e Transcripts (Parts A and B) by Randomised 
TreatmentSeparate pages for each gene and 
sample type (blood/biopsy) . 
Include band from FC -1 to 1, 
transparency 0.5SAC2 [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
9512.10.13. ICH Listings
ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programmi ng NotesDeliverable 
[Priority]
Subject Disposition
1. All Subjects ES7 Listing of Reasons for Screen Failure by Randomised Treatment Journal GuidelinesIA SAC [1]
SAC [1]
2. Safety ES2 Listing of Reasons for Study Withdrawal by Randomised 
TreatmentICH E3IA SAC [1]
SAC [1]
3. Safety SD2Listing of Reasons for Study Treatment Discontinuation by 
Randomised TreatmentICH E3 IA SAC [1]
SAC [1] 1]
4. Safety BL1 Listing of Subjects for Whom the Treatment Blind was Broken 
During the Study by Randomised TreatmentICH E3 IA SAC [1]
SAC [1]
5. Safety TA1 Listing of Planned and Actual TreatmentsIDSL IA SAC [1]
SAC [1] [1]
Protocol Deviations
6. Safety DV2Listing of Important Protocol Deviations by Randomised 
TreatmentICH E3 IA SAC [1]
SAC [1]
7. SafetyIE3 Listing of Subjects with Inclusion/Exclusion Criteria Deviations
by Randomised TreatmentICH E3IA SAC [1]
SAC [1] 1]
Populations Analysed
8. Safety SP3Listing of Subjects Excluded from Any Population by 
Randomised TreatmentICH E3 IA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
96ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programmi ng NotesDeliverable 
[Priority]
Demographic and Baseline Characteristics
9. Safety DM2 / DM4Listing of Demographic Characteristics by Randomised 
TreatmentICH E3IA SAC [1]
SAC [1]
10. Safety DM9 / DM10 Listing of Race by Randomised Treatment ICH E3IA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
97ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programmi ng NotesDeliverable 
[Priority]
11. Safety DM2Listing of Ulce rativeColitis Baseline Characteristics by 
Randomised TreatmentTo include:
Baseline Mucosal Appearance at 
Endoscopy Mayo Subscore, Baseline 
Total Mayo Score, 
Baseline Partial Mayo Score Baseline 
3-domain Mayo Score, Baseline UCEIS 
Total Score, Baseline M odified Riley 
Scale Score 
Baseline FCP, 
Baseline FCP category, 
Baseline Concomitant Medications for 
UC (Glucocorticoids only, 
Immunosuppressants only, 
Glucocorticoids and 
Immunosuppressants, No 
Glucocorticoids or 
Immunosuppressants, 
Baseline Prednisone dose,
Family History of Premature Coronary 
Artery Disease and History of Tobacco 
Use.
Include the footnote:
Note: Glucocorticoids and 
Immunosuppressants were identified by 
review of all ingredients by clinical and 
medical team.IA SAC [1]
SAC [1]
Prior, Current and Concomitant Medications
12. Safety MH2 Listing of Medical Conditions by Randomised TreatmentIA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
98ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programmi ng NotesDeliverable 
[Priority]
13. Safety CP_CM3 Listing of Concomitant Medications by Randomised TreatmentIDSL IA SAC [1]
SAC [1]
Exposure and Treatment Complia nce
14. Safety EX3 / EX4 Listing of Exposure Data by Randomised Treatment ICH E3IA SAC [1]
SAC [1]
15. Safety COMP3A/ 
COMP3BListing of Drug Accountability Data by Randomised TreatmentIA SAC [1]
SAC [1]
Adverse Events
16.SafetyAE9CP Listing of All Advers e Events by Period Treatment ICH E3IA SAC [1]
SAC [1]
17.SafetyAE7Listing of Subject Numbers for Individual Adverse Events by 
Period TreatmentICH E3IA SAC [1]
SAC [1] 1]
18.SafetyAE2Listing of Relationship Between Adverse Event System Organ 
Classes, Preferred Terms, and Verbatim TextIDSLIA SAC [1]
SAC [1] ]
Serious and Other Significant Adverse Events
19.SafetyAE9CPa Listing of Fatal Serious Adverse Events by Period Treatment ICH E3IA SAC [1]
SAC [1]
20.SafetyAE9CPaListing of Non -Fatal Serious Adverse Events by Period 
TreatmentICH E3IA SAC [1]
SAC [1]
21.SafetyAE14Listing of Reasons for Considering as a Serious Adverse Even t
by Period Treatment ICH E3IA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
99ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programmi ng NotesDeliverable 
[Priority]
22. Safety AE9CPListing of Adverse Events Leading to Withdrawal from Study / 
Permanent Discontinuation of Study Treatment by Period 
TreatmentICH E3IA SAC [1]
SAC [1]
23.SafetyAE9CP Listing of Other Significant Adverse Events by Period Treatment ICH E3IA SAC [1]
SAC [1] [1]
24.Safety
PSRAE1Listing of Possible Suicidality -Relate d Adverse Event Data: 
Event and Description (Se ction 1-Section 2) by Period 
TreatmentIDSLIA SAC [1]
SAC [1]
25.Safety
PSRAE2Listing of Possible Suicidality -Related Adverse Event Data: 
Event and Description (Sections 1 -Section 2) by Period 
TreatmentIDSLIA SAC [1]
SAC [1] 1]
26.SafetyPSRAE3Listing of Possible Suicidality -Related Adverse Event Data: 
Possible Cause(s) (Section 3) by Period TreatmentIDSLIA SAC [1]
SAC [1]
27.SafetyPSRAE4Listing of Possible Suicidality -Related Adverse Event Data 
(Sectio n 4) by Period TreatmentIDSLIA SAC [1]
SAC [1] 1]
Hepatobiliary (Liver)
28. Safety MH2Listing of Medical Conditions for Subjects with Liver Stopping 
Events by Period TreatmentIDSLIA SAC [1]
SAC [1] ]
29. Safety SU2Listing of Substance Use for Subjects wit h Liver Stopping 
Events by Period TreatmentIDSLIA SAC [1]
SAC [1] [1]
All Laboratory
30.SafetyLB5 Listing of All Laboratory Data for Subjects with Any Value of 
Potential Clinical Importance by Period TreatmentICH E3 IA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
100ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programmi ng NotesDeliverable 
[Priority]
31.SafetyLB5 Listing of Laboratory Values of Potential Clinical Importance by 
Period TreatmentIA SAC [1]
SAC [1] [1]
32.SafetyLB14Listing of Laboratory Data with Character Results by Period 
TreatmentICH E3 IA SAC [1]
SAC [1] ]
33.SafetyUR2AListing of Urinalysis Data for Subjects with Any Value of 
Potential Clinical Importance by Period TreatmentICH E3 IA SAC [1]
SAC [1]
34.Safety
LB5 Listing of Lipids Outside of the Normal Range by Period 
TreatmentLipids parameters = LDL 
Cholesterol, HDL Cholesterol, Total 
Cholest erol Triglycerides and
Cholesterol/HDL ratio
Include fasted statusIA SAC [1]
SAC [1]
ECG
35. Safety EG3*Listing of All ECG Values for Subjects with Any Value of 
Potential Clinical Importance by Period Treatment (including 
manually corrected values)IDSL EG3 plus extra columns for 
Manually Calculated QTcBand 
QTcF .  Highlighted provided Q Tc 
value
See 203168 Listing 89 for shell
Include absolute PCI subjects.
Footnote: H=High absolute, L= Low 
absolute.
* Provided QTc IA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
101ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programmi ng NotesDeliverable 
[Priority]
36. Safety EG3*Listing of All ECG Changes for Subjects with a Value of 
Potential Clinical Importance by Period Treatment (including 
manually corrected values)Include change from baseline or 
change from screening PCI 
subjects. 
IDSL EG3 plus extra columns for 
Manually Calcula ted QTcB and 
QTcF.  Highlighted provided QTc 
value
Footnote:  H=High change from 
baseline value, L= Low change from 
baseline value
* Provided QTcIA SAC [1]
SAC [1]
37. Safety EG3 Listing of ECG Values of Potential Clinical Importance by Period 
Treatment (including manually corrected values)"Include absolute PCIs. 
IDSL EG3 plus extra columns for 
Manually Calculated QTcB and 
QTcF.  Highlighted provided QTc 
value
Footnote: H=High absolute, L= Low 
absolute."
* Provided QTcIA SAC [1]
SAC [1] ] 
 
 2019N425893_00
CON FIDENTIA L
202152
102ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programmi ng NotesDeliverable 
[Priority]
38. Safety EG3Listing of ECG Changes of Potential Clinical Importance by 
Period Treatment (including manually corrected values)"Include change from baseline 
PCIs. 
IDSL EG3 plus extra columns for 
Manually Calculated QTcB and 
QTcF.  Highlighted provided QTc 
value
Footnote: H=High change, L= Low 
change."IA SAC [1]
SAC [1]
39. Safety EG5Listing of All ECG Findings for Subjects with an Abnormal ECG 
Finding by Period TreatmentIDSL IA SAC [1]
SAC [1]
40. Safety EG5 Listing of Abnormal ECG Findings by Period TreatmentIDSL IA SAC [1]
SAC [1]
Vital Signs
41. Safety VS4 / VS5Listing of All Vital Signs Data for Subjects with Any Value of 
Potential Clinical Importance by Period TreatmentIDSL IA SAC [1]
SAC [1]
42. Safety VS4 / VS5Listing of Vital Signs of Potential Clinical Importance by Period 
TreatmentIDSL IA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
10312.10.14. Non- ICH Listings
Non-ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
CSSRS
43. Safety ECSSRS4Listing of C- SSRS Suicidal Ideation and Behaviour Data by 
Period TreatmentIA SAC [1]
SAC [1]
44. Safety ECSSRS5Listing of C- SSRS Suicidal Behaviour Details by Period 
TreatmentIA SAC [1]
SAC [1]
PK
45. PKPK07 Listing of GSK2982772 Pharmacokinetic Concentration -Time 
DataSeparate listings for Blood and 
Biopsy dataIA SAC [1]
SAC [1]
Efficacy
46. SafetyLS2 Listing of Individual Mayo S ubscores by Randomised 
TreatmentIA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
104Non-ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
47. Safety LS2 Listing of Mayo Data by Randomised TreatmentActual and Change from Baseline 
in Total Mayo, Partial Mayo and 3-
domain Mayo Scores .
Proportion of Subjects Achieving 
Endoscopy Remission, Mayo 
Clinical Response , 3-domain Mayo 
Clinical Response, Mayo Clinical 
Remission and 3 -domain Mayo 
Clinical Remission.
Add variables which determine if 
the subjects arein the P P and /or 
PP + Completer sPopulation.IA SAC [1]
SAC [1]
48. SafetyLS2Listing of Individual UCEIS Scores by Randomised TreatmentIA SAC [1]
SAC [1]
49. Safety LS2 Listing of UCEIS Data by Randomised TreatmentActual and Change from Baseline 
in UCEIS Total Score 
Proportion of Subjects Achieving 
UCEIS Remission IA SAC [1]
SAC [1]
50. SafetyLS2 Listing of Actual and Change from Baseline in CRP by 
Randomised TreatmentIA SAC [1]
SAC [1]
51. Safety LS2Listing of Actual and Log -transformed Change from Baseline in 
FCP by Randomised TreatmentIA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
105Non-ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
52. Safety LS2Listing of Actual and Change from Baseline in Modified Riley 
Scale Score by Randomised TreatmentIA SAC [1]
SAC [1]
53. Safety LS2Listing of Actual and Change from Baseline in RHI Score by
Randomised TreatmentIA SAC [1]
SAC [1]
54. Safety LS2Listing of Actual and Change from Baseline in Geboes Index 
Total Score by Randomised TreatmentIA SAC [1]
SAC [1]
55. Safety LS2Listing of Actual and Change from Baseline in IBDQ Domains 
and Total Sc oreby Randomised TreatmentSAC [1]
56. Safety EFF_L1Listing of Subject Symptom Diary Card Data by Randomised 
TreatmentUse the decodes specified in RAP 
Section 12.6.4 and not codelist 
defined in FCEORS.SAC [1]
57. Safetyn/aRaw SAS output of Statistical Analysis Results for GEE 
Analysis for Subjects Achieving Mayo Endoscopic Remission 
(Parts A and B) by Randomised TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one 
treatment group.IA SAC [1]
SAC [1]
58. PPn/aRaw SAS output of Statistical Analysis Results for GEE 
Analysis for Subjects Achieving Mayo Endoscopic Remission 
(Parts A and B) by Randomised TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one 
treatment group.IA SAC [1]
SAC [1]
59.PP + 
Completersn/aRaw SAS output of Statistical Analysis Results for GEE 
Analysis for Subjects Achieving Mayo Endoscopic Remission 
(Parts A and B) by Randomised TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one 
treatment group.IA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
106Non-ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
60. Safety n/aRaw SAS Output of Statistical Analysis Results for GEE 
Analysis for Subjects Achieving Mayo Clinical Response. 3 -
domain Mayo Clinical Response, Mayo Clinical Remission and 
3-domain Mayo Clinical Remission (Parts A and B) by 
Randomised TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one 
treatment group.IA SAC [1]
SAC [1]
61. PP n/aRaw SAS Output of Stati stical Analysis Results for GEE 
Analysis for Subjects Achieving Mayo Clinical Response. 3 -
domain Mayo Clinical Response, Mayo Clinical Remission and 
3-domain Mayo Clinical Remission (Parts A and B) by 
Randomised TreatmentGEE modelling will only be 
perform ed if at least 30% response 
rate at Day 85 for any one 
treatment group.IA SAC [1]
SAC [1]
62.PP + 
Completersn/aRaw SAS Output of Statistical Analysis Results for GEE 
Analysis for Subjects Achieving Mayo Clinical Response. 3 -
domain Mayo Clinical Response, Mayo Clinical Remission and 
3-domain Mayo Clinical Remission (Parts A and B) by 
Randomised TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 for any one 
treatment group.IA SAC [1]
SAC [1]
63. Safety n/aRaw SAS Output o f Statistical Analysis Results for MMRM 
Analysis of the Change from Baseline in Total, Partial and 3 -
domain Mayo Scores (Parts A and B) by Randomised 
TreatmentIA SAC [1]
SAC [1]
64. PP n/aRaw SAS Output of Statistical Analysis Results for MMRM 
Analysis of the Change from Baseline in Total, Partial and 3 -
domain Mayo Scores (Parts A and B) by Randomised 
TreatmentIA SAC [1]
SAC [1]
65.PP + 
Completersn/aRaw SAS Output of Statistical Analysis Results for MMRM 
Analysis of the Change from Baseline in Total, Pa rtial and 3 -
domain Mayo Scores (Parts A and B) by Randomised 
TreatmentIA SAC [1]
SAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
107Non-ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
66. Safety n/aRaw SAS Output of Statistical Analysis Results for MMRM 
Analysis of the Change from Baseline in UCEIS Total Score 
(Parts A and B) by Randomised Treatmen tIA SAC [1]
SAC [1]
67. Safety n/aRaw SAS Output of Statistical Analysis Results for GEE 
Analysis for Subjects Achieving UCEIS Remission (Parts A and 
B) by Randomised TreatmentGEE modelling will only be 
performed if at least 30% response 
rate at Day 85 f or any one 
treatment group.IA SAC [1]
SAC [1] ]
68. Safety n/aRaw SAS Output of Statistical Analysis Results for MMRM 
Analysis of the Change from Baseline in CRP (Parts A and B) 
by Randomised TreatmentIA SAC [1]
SAC [1]
69. Safety n/aRaw SAS Output of Stat istical Analysis Results for MMRM 
Analysis of the Change from Baseline in Log -Transformed FCP 
(Parts A and B) by Randomised Treatment IA SAC [1]
SAC [1]
70. Safety n/aRaw SAS Output of Statistical Analysis Results for MMRM 
Analysis of the Change from Base line in Modified Riley Scale 
Score (Parts A and B) by Randomised TreatmentIA SAC [1]
SAC [1]
71. Safety n/aRaw SAS Output of Statistical Analysis Results for MMRM 
Analysis of the Change from Baseline in RHI Score (Parts A 
and B) by Randomised TreatmentIA SAC [1]
SAC [1]
72. Safety n/aRaw SAS Output of Statistical Analysis Results for MMRM 
Analysis of the Change from Baseline in Geboes Index Total 
Score (Parts A and B) by Randomised TreatmentIA SAC [1]
SAC [1] ]
73. Safety n/aRaw SAS Output of Statistical Analysis Results for MMRM 
Analysis of the Change from Baseline in IBDQ Total Score 
(Parts A and B) by Randomised TreatmentSAC [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
108Non-ICH: Listings
No. PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable 
[Priority]
Biomarker
74. SafetyPD_L1 Listing of Inflammatory Biomarkers in Biopsy Tissue by 
Randomised TreatmentSAC [1]
75. SafetyPD_L 2 Listing of TEAR1 Concentrations % Target Engagement and 
Pathway Engagement by Randomised TreatmentSeparate listings for Blood and 
Biopsy TissueSAC [1]
76. Safety PD_L3Listing of mRNA Expression of Inflammatory Gene Transcripts 
by Randomised TreatmentSeparate listings for Blood and 
Biopsy TissueSAC [1]
77. Safety n/aRaw SAS Output of Statistical Analysis of Biopsy Tissue 
Inflammatory Biomarkers (Parts A and B) by Randomised 
TreatmentSAC [1]
78. Safety n/aRaw SAS Output of Statistical Analysis of TEAR1 % Target 
Engagement in Blood (Parts A and B) by Randomised 
TreatmentSAC [1]
79. Safety n/aRaw SAS Output of Statistical Analysis of TEAR1 % Target 
Engagement in Biopsy Tissue (Parts A and B) by Randomised 
TreatmentSAC [1]
80. Safety n/aRaw SAS Output of S tatistical Analysis of Pathway 
Engagement in Blood (Parts A and B) by Randomised 
TreatmentSAC [1]
81. Safety n/aRaw SAS Output of Statistical Analysis of Pathway 
Engagement in Biopsy Tissue (Parts A and B) by Randomised 
TreatmentSAC [1]
82. Safety n/aRaw SAS Output of Statistical Analysis of mRNA Expression in 
Blood (Parts A and B) by Randomised TreatmentSAC2 [1]
83. Safety n/aRaw SAS Output of Statistical Analysis of mRNA Expression in 
Biopsy Tissue (Parts A and B) by Randomised TreatmentSAC2 [1] 
 
 2019N425893_00
CON FIDENTIA L
202152
10912.11. Appendix 11: Example Mock Shells for Data Display s
Data Display Specification will be made available on Request 
 
 2019N425893_00
CON FIDENTIA L
202152
11012.12. Appendix 12: NONMEM datafile specification
GSK to produce based on 203176 dataspec file 
 
 2019N425893_00